


FORM PTO-1390 (REV 11-98)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 2554-7
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/485845 Unknown
INTERNATIONAL APPLICATION NO. PCT/US98/17232	INTERNATIONAL FILING DATE 20 August 1998	PRIORITY DATE CLAIMED 22 August 1997
TITLE OF INVENTION NOVEL AMIDE DERIVATIVES		
APPLICANT(S) FOR DO/EO/US FUNAMIZU et al		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
- ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
- ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - ☒ has been transmitted by the International Bureau.
 - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - ☐ have been transmitted by the International Bureau.
 - ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
 - ☐ have not been made and will not be made.
- ☒ A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)).
- ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. To 16. Below concern document(s) or information included:

- ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
- ☐ A substitute specification.
- ☐ A change of power of attorney and/or address letter.
- ☒ Other items or information. PTO-1449 and International Search Report

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 097/185845		INTERNATIONAL APPLICATION NO. PCT/US98/17232		ATTORNEY'S DOCKET NUMBER 2554-7	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): -- Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$970.00 -- International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$840.00 -- International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$760.00 -- International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$670.00 -- International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)\$96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	670.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	32	-20 =	12	X	\$18.00
Independent Claims	7	-3 =	4	X	\$78.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)					+\$260.00
TOTAL OF ABOVE CALCULATIONS =				\$	1328.00
Reduction by 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).					0.00
SUBTOTAL =				\$	1328.00
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					0.00
TOTAL NATIONAL FEE =				\$	1328.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property					0.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1,210 - Small Entity Fee = \$605)					0.00
TOTAL FEES ENCLOSED =				\$	1328.00
				Amount to be:	
				refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1328.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201 Telephone: (703) 816-4000					
 SIGNATURE					
Arthur R. Crawford NAME					
25,327			February 17, 2000		
REGISTRATION NUMBER			Date		

PROCESSED 26 APR 2000

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

FUNAMIZU et al

Atty. Ref.: **2554-7**

Serial No. **09/485,845**

Group:

Filed: **February 17, 2000**

Examiner:

For: **NOVEL AMIDE DERIVATIVES**

* * * * *

April 26, 2000

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the claims as follows:

IN THE CLAIMS

Claim 24, line 4, delete "any one of Claims 1 to 15" and insert -- claim 1 --.

REMARKS

The above amendment is made to delete the multiple dependency and place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:


Arthur R. Crawford

Reg. No. **25,327**

ARC:Imy

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

FUNAMIZU et al

Atty. Ref.: 2554-7

Serial No. **Unknown**

Group:

Filed: **February 17, 2000**

Examiner:

For: **NOVEL AMIDE DERIVATIVES**

* * * * *

February 17, 2000Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Prior to calculation of the filing fee and in order to place the above identified application in better condition for examination, please amend the claims as follows:

IN THE CLAIMS

Claim 16, line 3, delete "any one of Claims 1 to 15" and insert -- claim 1 --.

Claim 17, line 3, delete "any one of Claims 1 to 15" and insert -- claim 1 --.

Claim 18, line 3, delete "any one of Claims 1 to 15" and insert -- claim 1 --.

Claim 19, lines 3 and 4, "any one of Claims 1 to 15" and insert -- claim 1 --.

Claim 21, lines 2 and 3, delete "any one of Claims 1 to 15" and insert

-- claim 1 --.

Claim 22, line 3, delete "any one of Claims 1 to 15" and insert -- claim 1 --.

Claim 23, line 4, delete "any one of Claims 1 to 15" and insert -- claim 1 --.

FUNAMIZU et al
Serial No. Unknown


REMARKS

The above amendments are made to place the claims in a more traditional
format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:


Arthur R. Crawford

Reg. No. 25,327

ARC:Imy

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

NOVEL AMIDE DERIVATIVESField of the invention

5 The present invention related to synthetic peptidomimetics having growth hormone releasing activity in humans or animals, and their use in humans for treating medical disorders resulting from a deficiency in growth hormone, or use in animals for increasing the rate and extent of growth, or for increasing the milk or wool production, or for treatment of ailments.

Background of the invention

10 Growth hormone, which is secreted from the pituitary, stimulate growth of all tissues of the body that are capable of growing. In addition, growth hormone is known to have following basic effects on the metabolic process of the body:

15 1)Increase the rate of protein synthesis in the cells of the body, 2)Decrease rate of carbohydrate utilization in the cells of the body; 3)Increase mobilization of the fatty acids and use of the fatty acids for the energy.

Artificial manipulation of growth hormone levels has been demonstrated to have significant therapeutic utility. Human growth hormone supplementation has been shown to be an effective treatment for growth hormone deficiency and their related diseases states in humans, such as short statue (Robinson and Clark., Growth Hormone: Basic and Clinical Aspect, Isaksspn, Binder, Hall and Hokfelt eds., Amsterdam, p109-127(1987).

20 Apart from this application, studies have uncovered new and significant properties of growth hormone which lend further importance to the ability to control growth hormone levels. For example, recent clinical studies indicate that growth hormone supplementation may be useful in combating the maladies of aging in humans. Elevated growth hormone levels in animals also have been shown to result in increase lean mass muscle. One application of this latter observation could results in higher production of leaner meat products or larger and /or stronger animals. However, their clinical and /or animal application, as with recombinant growth hormone, has been limited due to their high cost and lack of oral efficiency (Low,L.C.K.,Neuroendocrinology,1991,53 (Supp.1), 37-40: Thomer, M.O., Acta

25
30

Pediatr 1993,388 (Suppl),2-7).

The release of growth hormone from pituitary organs is under tight control of a second protein, growth hormone releasing factor (GRF), which is also commonly known in the art as somatomedin, growth hormone releasing hormone (GHRH), growth releasing hormone (GRH) and neurotransmitters either directly or

35

indirectly. Growth hormone release can be stimulated by growth hormone releasing hormone and inhibited by somatostatin. In both cases the hormones are released from the hypothalamus but their action is mediated primarily via specific receptors located in the pituitary. As a result, the development of synthetic growth hormone releasing agents and the use of drugs acting through established neurotransmitter systems in the brain to stimulate growth hormone releasing are being considered as alternative to highly expensive and lack of oral efficiency growth hormone replacement therapy for the restoration on normal serum growth hormone levels (Pharm.Rev.,46,1-33(1994)).

Even before the discovery of the endogenous releasing factor GHRH in 1982 (Guillemin, R.etal.,Science,1982,218:585-587), Bowers and co-workers had reported on a series of peptides derived from Leu and Met enkephalins which specifically release growth hormone from pituitary(Bowers, C.Y. et al., Molecular Endocrinology. MacIntyne I (Ed.) Elsevier /North Holland Biomedical Press, Amsterdam 1977,287-292). It was later discovered that these growth hormone releasing peptides (GHRPs) act directly on the pituitary through a different signal transduction pathway from that of GHRH. In combination with GHRH, GHRPs act synergistically at the pituitary to release growth hormone. A hypothalamic binding site for GHRPs, which may be partially responsible for their growth hormone releasing in vivo by releasing endogenous GHRH, has been identified (Codd,E.E. et al., Neuropharmacology, 1989,28,1139-1144; Howard,D.H. et al.,Science,1996, 273, 974-976). Momany and Bowers employed molecular modeling techniques to discovered the growth hormone releasing hexapeptide GHRP-6, which is extremely potent and specific growth hormone secretagogue in human. More potent analogs of GHRP-6 have recently discovered and presently under clinical evaluation (Laron,A. Drugs,1995,50,595-601). While GHRP-6 is a much more smaller peptide than either recombinant growth hormone or growth hormone releasing hormone, it still has low oral bioavailability in human(0.3%). However, GHRP-6 has demonstrated that relatively small molecule, with its possible advantage of lower cost and oral bioavailability, may be a viable alternative to subcutaneous treatment with recombinant growth hormone (DeVita,R.J. et al.,Drugs of the Future,1996,21(3), 273-281).


His-D-Trp-Ala-Trp-D-Phe-Lys-NH ₂	GHRP-6
Ala-His-D-β-Nal-Ala-Trp-D-Phe-Lys-NH ₂	GHRP-1
D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH ₂	GHRP-2 (KP-102)
His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH ₂	Hexarelin

In recent years significant efforts have been taken to develop non-peptidyl analogs of this series of compounds. Such compounds, termed growth hormone

secretagogues, should be orally bioavailable, induce production or release of growth hormone, and act as synergistically with growth hormone releasing hormone.


Representative growth hormone secretagogues are disclosed in USP 3,239,345; USP 4,036,979; USP 4,411,890; USP 5,206,235 ; USP 5,248,841; USP 5,310,017; USP 5,310,737; USP 5,434,261; USP 5,552,385; USP 5,559,128; EP 144,230; EP 513,974; WO 94/07486; WO 94/08583; WO 94/11012; WO 94/13696; WO 95/03290; WO 95/09633; WO 95/12598; WO 95/13069; WO 95/14666; WO 95/16692; WO 95/16675; WO 95/17422; WO 95/17423; WO 95/34311; WO 96/02530; WO 96/05195; WO 96/13265; WO 96/15148; WO 96/22997; WO 96/24587; WO 96/35713; WO 96/38471; WO 97/00894; WO 96/24580; WO 97/06803; WO 97/07117; WO 97/11697; WO 97/15191; WO 97/22620; WO 97/23508; WO 97/24369 and Science, 260, 1640-1643 (1993), the entire of all of which are herein incorporate by reference.

USP 5,206,235 issued April 27, 1993, describes a series of benzolactam compounds typified by the following structure. These compounds have demonstrated



clinical activity in humans in raising the growth hormone secretory levels (B.J. Gertz., Journal of Clinical Endocrinology and Metabolism, 77, 1393-1397 (1993)).

Second generation of growth hormone secretagogues is described in WO 94/13696, WO 96/15148. These compounds are typified by the following structure.



A number of these compounds are reported to be safe and effective in promoting endogenous growth hormone release in humans, however, there remain problems with oral availability and specificity.

Summary of the invention

5 The instant invention is directed to certain novel amide compounds which have the ability to stimulate the release of natural or endogenous growth hormone. It is a still further object of this invention to provide more potent growth hormone secretagogues than those of the prior, especially "GHRP-6", "GHRP-1", "GHRP-2(KP-102)", "L-692,429", "L-692,585", "MK-0677" and "G07220". It is a further object to provide growth hormone secretagogues that are specific for growth hormone release and do not cause significant release of other hormones, especially; LH, FSH, TSH, ACTH, prolactin, vasopressin, oxytocin, insulin, and cortisol. The compounds thus have the ability to be used to treat conditions which require the stimulation of growth hormone production or in animals used for food, wool, and milk production where the stimulation of growth hormone will result in a large, more productive animals. Thus, it is an object of the present invention to describe the compounds. It is a further object of this invention to describe procedures for the preparation of such compounds and intermediates. A still further object is to describe the use of such compounds to increase the secretion of growth hormone in humans and animals. It is a still further object to provide compositions containing the compounds for the use of treating humans and animals so as to increase the levels of growth hormone secretions. These and other objects of the invention will be apparent from the following specification.

The strategy of lead finding and lead optimization

25 It is the object of this invention to provide a novel class of non-peptidyl growth hormone secretagogues using an approach of computer-aided rational drug design and discovery. The computational strategy described below has produced 3D pharmacophores for 3D database search in the lead finding, and provided site-dependent quantitative structure activity relationship(QSAR) for fragment property refinement in the lead optimization, leading to the development of novel
30 potent growth hormone secretagogues. The computational strategy has been implemented through three stages in the invention:

- (1) conceptual stage - generation and validation of 3D-pharmacophores
- (2) discovery stage - database search and compound modification
- (3) optimization stage - development of QSAR for refinement

(1) Conceptual Stage - Pharmacophore Development

The structural components of the growth hormone releasing peptides (GHRPs) and non-peptidyl derivatives are important for their growth hormone releasing potency. It is thus the crucial step in rational design to develop 3D

5 pharmacophores, which represent the three dimensional arrangement of functional groups essential for activity, from a number of compounds with known activities, similar mechanism of action, and similar in vivo properties. The seven potent peptides selected for pharmacophore generation in the present invention include "GHRP-6", "[D-Lys⁶]GHRP-6", "KP102(GHRP-2)", and its four peptidyl analogs. 10 Non-peptidyl analogs chosen for pharmacophore development include "L-692,429", "L-692,585", "MK-0677", and "L-164,080". In addition, one inactive peptide "[Val³]GHRP-6", and one inactive non-peptide "L-692,428" were used as control. Conformations of each of these compounds were generated using a strategy of repeated cycles of high (900°K) and low (300°K) temperature molecule dynamics 15 combined with energy minimization of molecule structures. Details of this strategy are described by Chew, C. et al. (Mol. Pharm., 1991, 39, 502). The calculations were performed using Quanta/CHARMm 4.0 (Molecular Simulation, Inc. USA). The search for the form in which flexible molecules such as peptides bind to receptors is a challenging task because many low-energy conformations are accessible and 20 they coexist in equilibrium. The complexity increases enormously when several diverse families of fairly flexible molecules are included and the goal is to identify the common geometric arrangements of moieties that are determinants of receptor recognition or activation because all low-energy conformations of each molecule should be included in analysis. A novel computer program, DistComp, was thus 25 developed to perform systematic and automated comparisons of molecular conformations in different compounds for the determination of 3D pharmacophores (Huang, P. et al., J. Computer-Aided Molecular Design., 1997, 11, 21-28). DistComp provides a procedure for identifying common spatial arrangements of selected moieties in a given set of molecules. No prior assumption of an active conformation 30 is necessary. There is also need for a rigid template. However, central to this procedure is the selection of sets of common functional moieties assumed to be important for recognition or activation. The validity of these candidate recognition or activation sites is then assessed by the program: for each hypothetical set of recognition or activation moieties selected, the program systematically determines 35 whether any common 3D relationships among them exists in active analogs but are absent in inactive ones. Each set of proposed chemical moieties that satisfies this requirement, together with the common spatial arrangements identified, comprises candidate 3D pharmacophores.

Using the program DistComp, a convergent model termed "Pharmacophore I" which is common to all seven peptides and two non-peptides ("L-692,429", "L-692-585") was successfully developed. "Pharmacophore I" was subsequently validated using two new potent growth hormone secretagogues, "G-7220", "G-7134", developed at Genentech by that time with the results indicating that the two compounds fit well to the pharmacophore. Another convergent model, termed "Pharmacophore II", was developed when "MK-0677" and "L-164,080" were reported by Merck to be potent growth hormone secretagogues. "Pharmacophore II" is common to all seven peptides and two non-peptides, "MK-0677" and "L-164,080". Pharmacophore I and II have some common features, but differ in two components.

(2) Discovery Stage-Database Search and Compound Modification

The successful development of the 3D pharmacophores provides a logical framework for the design and discovery of novel growth hormone secretagogues in the present invention. Using these 3D pharmacophores, 3D database search was performed of a number of databases including MDDR, Chapman & Hall Database of Organic Compounds, Maybridge, CAS30K, and NCI Database. Both 3D rigid and flexible search methods were used. While a rigid search does static comparison of the 3D structure stored in database of a compound with the pharmacophore, a flexible search takes into account molecular flexibility. Compounds obtained from database search were then screened and modified using structural and chemical intuition, with emphasis on scaffold novelty, conformational rigidity, minimum extra components, and chemical aspects such as excluding compounds that are polymeric, clathrate, molecular complex, metal complex, toxic, or peptides. Modification of compounds was performed mainly on compounds that have novel scaffolds. Subsequent computer modeling studies were then performed on compounds from the database search which had been either modified or obtained from a flexible search, in order to determine the extent to which they conformed either Pharmacophore I or II. Candidates which were found to be consistent with the pharmacophores and easy to synthesize were then selected for synthesis and pharmacological testing. Using these strategies, initial lead compounds in the present invention have been successfully designed and discovered.

(3) Optimization Stage - Development of QSAR for Refinement

The goal in this stage was to enhance the activity of initial lead compounds from, typically, micromolar into the nanomolar range. While experimentalists focused on making various analogs of the leads for SAR studies, computational efforts focused on the development of site-dependent QSAR (Quantitative Structure Activity Relationship) procedure embodied in a suite program, for refinement of the lead compounds. The innovative approach is in addition to

improving compounds by making them more consistent with the pharmacophores in terms of the three-dimensional arrangement/location of the functional groups.

Preliminary investigation were performed that demonstrated no significant correlation between the overall molecular properties of growth hormone releasing peptides and their activity. Clearly, growth hormone secretion activity cannot be described simply by these molecular descriptors. A possible explanation for this is that the overall molecular descriptors can be significantly modulated by the molecular regions which are not important to the drug-receptor interaction. As we have already experienced in many cases, complex drug interactions cannot be simply described by overall descriptors of a molecule.

A novel site-dependent QSAR method was, therefore, developed to specifically identify the function of each pharmacophoric site that comprise the 3D pharmacophores. These supplementary requirements of site-dependent properties were used as additional criteria for optimizing and refining novel compounds on the basis of 3D pharmacophore. The most challenging aspect of this task was to identify and calculate relevant properties of each pharmacophoric site (i.e. site-dependent properties) rather than the properties of the entire molecule. These properties can be used in a regression analysis to identify the ones that modulate activity. Among the library of properties that can be calculated for each site are: 1) regional net atomic charges; 2)polarizability; 3)free energy of solvation; 4)Van der Waals volume; 5)hydrophobicity; 6)proton donating ability; 7)proton accepting ability; 8)molecular flexibility. A prerequisite to use of this site-dependent QSAR procedure is the definition of the pharmacophoric sites or fragments that comprise an already identified 3D pharmacophore. A pharmacophoric site in a molecule is defined as a fragment consisting of a pharmacophore atom (core), which is a component in 3D Pharmacophore, together with its immediate neighbors in the molecule and capping atoms. The site-dependent QSAR studies have been performed on eight peptides including "GHRP-6", "[D-Lys⁶]GHRP-6", "G-7134", "KP-102" and its four peptidyl analogs. The results demonstrated clearly the correlation of some fragment properties, particularly hydrophobicity, in some specific regions in these molecules with their growth hormone secretion activity. These results provided a useful guide for modification of the specific pharmacophoric sites leading to enhanced activity.

(4)Summary


The computational strategies used here: extensive conformational studies and Distcomp analysis for a small number of known peptide and non-peptide analogs have led to the successful development of 3D pharmacophores for activation of growth hormone secretagogues agonists. These 3D activation pharmacophores

have provided the essential, enabling basis for the design and discovery of the novel non-peptidyl growth hormone secretagogues in this invention. Database search using the 3D pharmacophores together with strategies for compound screening and modification have led to the discovery of initial lead compounds. A

5 site-dependent QSAR developed for fragment property refinement has provided guidelines for lead optimization. These three steps-pharmacophore development, lead discovery and optimization- together have led to the development of the novel potent growth hormone secretagogues described in this invention.

Detailed description of the invention


Present invention provides the novel compounds presented by the structural Formula I :



I


wherein

- 5 A is a lipophilic group comprising an aliphatic bridging group, and
 B is a lipophilic group, and
 D is a group having at least one amino or substituted amino group, and
 R is hydrogen, alkyl, or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof.
- 10 In Formula I , A is preferably



wherein


A¹ is an aliphatic or aromatic ring which may have at least one hetero atom, and
 M¹ is substituted or unsubstituted alkylene.
 A¹ is preferably



- 15 wherein

A² is single or fused ring, each ring constituting A² is on aliphatic or aromatic ring which may have at least one hetero atom, each ring constituting A² may be substituted by at least one group selected from halogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, perfluoroalkyl, perfluoroalkoxy, cyano, nitro, substituted sulfonyl, substituted sulfenyl, substituted sulfinyl, mercapto, substituted carbonyl, amino, substituted amino, aryl, and substituted aryl, and

- 20 M¹ is alkylene which may be substituted by halogen, hydroxy, (C₁ - C₅)alkyl, and / or (C₁ - C₅)alkoxy.
- 25 A¹ is more preferably



wherein

A^3 is a 5, 6, or 7 membered aromatic ring which may be comprised of at least one hetero atom, and may be substituted by a group selected from halogen, hydroxy, $(C_1 - C_5)$ alkyl, $(C_1 - C_5)$ alkoxy, $(C_1 - C_5)$ perfluoroalkyl, $(C_1 - C_5)$ perfluoroalkoxy, nitro, cyano, substituted sufonyl, substituted sulfenyl, substituted sulfinyl, mercapto, amino, substituted amino, substituted carbonyl, phenyl and / or substituted phenyl, and

A^3 can be fused with at least 5 to 8 membered aliphatic or aromatic ring which may be consisted of at least one hetero atom, and

l is 0, 1, or 2, and


X is $-CH_2-$, $-O-$, $-S(O)r-$, $-C(O)-$, $-C(S)-$, $-CH=CH-$, $-CH(OH)-$, or $-NR^4-$, and

R^4 is hydrogen, $(C_1 - C_5)$ alkyl, $(C_3 - C_8)$ cycloalkyl, acyl, or alkoxycarbonyl, and m is 0, 1, or 2, and

Y is $-C(O)-$, $-C(S)-$, or $(C_1 - C_5)$ alkylene which may be substituted by $(C_1 - C_5)$ alkyl,

p is 0, 1, or 2, and


Z is substituted or unsubstituted $(C_1 - C_5)$ alkylene, $-NR^4-$, or



wherein

A^4 is a 5 or 6 membered aromatic ring which may be comprised of at least one hetero atom, and

A^4 may be substituted by a group selected from halogen, hydroxy, $(C_1 \sim C_5)$ alkyl, $(C_1 - C_5)$ alkoxy, $(C_1 - C_5)$ perfluoroalkyl, $(C_1 - C_5)$ perfluoroalkoxy, nitro, cyano, amino, substituted amino, phenyl and / or substituted phenyl, or



wherein

G_1 and G_2 are independently carbon or nitrogen, and

one of --- may represent double bond when either G_1 and G_2 or G_2 and G_3 are carbon, and

- 5 G_3 , G_4 , and G_5 are independently $-\text{O}-$, $-\text{S}(\text{O})\text{r}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{S})-$, $-\text{CH}=\text{CH}-$, $-\text{CH}(\text{OH})-$, $-\text{NR}^4-$, or (C_1-C_5) alkylene, r is 0, 1, or 2, and n is 0 or 1.

Examples of preferred A^1 is include

- 10,11-Dihydrodibenzo[b,f][1,4]oxazepin-11-one,
 3,4-Dihydro-2H-quinoline,
 2-Oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocine,
 2,3-Dihydro-2,3-dihydro-indole,
 2-Oxo-3,4-dihydro-2H-quinoline,
 3-Oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazine,
 4-Methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepine,
 4,5-Dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11(10H,11aH)-dione,
 2,3-dihydro-benzo[1,4]thiazine,
 5,10,11,12-dihydro-6H-dibenzo[b,f]azocine,
 20 2-Oxo-2,3,4,5-tetrahydrobenzo[b]azepine,
 1,1,4-Trioxo-2,3-dihydro-benzo[1,5]thiazepine,
 4-Oxo-2,3-dihydro-1,5-benzothiazepine,
 5,11-Dihydro-dibenzo[b,e]azepine,
 5H-Dibenzo[b,e]azepin-6,11-dione,
 25 5H-Dibenzo[b,f]azocin-6-one,
 10H-Dibenzo[b,f][1,4]thiazepin-11-one,
 5-Oxo-5,10H-dibenzo[b,f][1,4]thiazepin-11-one,
 5,5-Dioxo-5,10H-dibenzo-[b,f][1,4]thiazepin-11-one,
 4-Oxo-2,3-dihydro-[1,5]benzoxazepine,
 30 6,2-Dioxo-6,6a,7,8,9,10-hexahydro-12H-benzo[e]pyrido[1,2-a][1,4]diazepine,
 2-Oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrole,
 Phenothiazine, which may have substituted,

In Formula I, B is preferably

B is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, or

- 35 aryl, arylalkyl or arylalkoxyalkyl which may be substituted on their aromatic ring.

B is more preferably

B is substituted or unsubstituted $(\text{C}_6-\text{C}_{20})$ alkyl, phenylalkyl, naphthylalkyl, 5,6,7,8-tetrahydro-naphthylalkyl, indolylalkyl, quinolylalkyl, or phenylalkoxyalkyl, which

may be substituted by a group selected from halogen, hydroxy, (C₁–C₅)alkyl, (C₁–C₅)alkoxy, nitro, cyano, amino, substituted amino, phenyl, or substituted phenyl.

In Formula I, D is preferably






or

wherein

- 5 R¹ is hydrogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl, and R² and R³ are independently hydrogen, alkyl, substituted alkyl, acyl, amidino, alkoxycarbonyl, or either R² or R³ can be taken together with R¹ to form alkylene, and R² and R³ can be taken together to form alkylene, or heterocycle, and

- 10 M² is :



wherein x, y and z are independently an integer of 0 to 4, and

R⁵, R⁶, R⁷ and R⁸ are independently hydrogen, halogen, alkyl, substituted alkyl, ---OR^9 , ---SR^9 , $\text{---NR}^9\text{R}^{10}$, ---NHC(O)R^9 , ---OCOR^9 , ---C(O)OR^9 , ---OC(O)OR^9 , $\text{---CONR}^9\text{R}^{10}$ or can be taken together with R¹ or R² to form alkylene or heterocycle,

- 15 R⁹ and R¹⁰ are independently hydrogen, alkyl, substituted alkyl, and

R⁹ can be taken together with R¹ or R² to form alkylene,

R⁵ and R⁷ or R⁶ and R⁸ can be taken together to form alkylene or heterocycle, or

R⁵ and R⁶ or R⁷ and R⁸ can be taken together with the carbon atom to which

R⁵ and R⁶, or R⁷ and R⁸ are bonded, respectively, to form carbonyl or thiocarbonyl or

- 20 imino, and

E is oxygen atom or sulfur atom.

Preferably combination is that

R¹ is hydrogen, (C₁–C₅)alkyl, (C₃–C₈)cycloalkyl, (C₁–C₅)hydroxyalkyl, or

(C₁—C₅)aminoalkyl, and

R² and R³ are independently hydrogen, (C₁–C₅)alkyl, substituted (C₁–C₅)alkyl,

(C₁–C₆)acyl, or (C₁–C₆)alkoxycarbonyl, and

R¹ and R² or R² and R³ are can be taken together to form alkylene,




















5 R⁵, R⁶, R⁷, and R⁸ are independently hydrogen, halogen, (C₁–C₅)alkyl, substituted (C₁–C₅)alkyl, –OR⁹, –SR⁹, –NR⁹R¹⁰, –OC(O)OR⁹, –NHC(O)R⁹, –C(O)OR⁹, and

























R⁵ can be taken together with R¹ or R² to form alkylene,

R⁹ and R¹⁰ are independently hydrogen, (C₁–C₅)alkyl, and

R⁹ can be taken together with R¹ or R² to form alkylene.

10 Examples of referred D include







Examples of preferred compounds of Formula I include

N-(2-Aminoethyl)-3-phenyl-2(R)-[2-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl) acetyl amino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;

3-(3-Acetyl amino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-N-[1(R)-(2-aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-(4-Amino-butyl)-3-(naphthalen-2-yl)-2(R)-[2-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)acetyl amino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H,(11aS)-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl)propionamide

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[3,2-b][1,4]oxazin-4-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;

- N-(2-Amino-2-methylpropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)-propionamide;
- 5 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)butyramide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(3-oxo-2,3-dihydrobenzo[1,4]thiazin-4-yl)butyramide;
- 10 N-[1(R)-(3-Methylaminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;
- N-[1(R)-(3-Methylaminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;
- N-(1(R)-[(3-Aminopropyl)-methylcarbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide
- 15 N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;
- N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-
- 20 [1,5]benzothiazepin-5-yl)butyramide;
- N-(1(R)-[Bis-(3-aminopropyl)-carbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;
- 25 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)butyramide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(phenothiazin-10-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-
- 30 11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;
- N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-propionylamino]-3-(naphthalen-2-yl)propionamide;
- N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]propionamide;
- 35 N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionylamino]propionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

- N-[1(R)-(2-aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(1H-indol-3-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;
- 5 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,4-dioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;
- 10 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-propionamide;
- 15 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H,(11aS)-pyrrolo[2,1-c][1,4]diazepin-10-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-
- 20 (phenothiazin-10-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)butyramide;
- N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalene-2-yl)ethyl]-3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;
- 25 N-(3-Amino-2-hydroxypropyl)-3-(naphthalene-2-yl)-2(R)-β-(4-oxo-7-trifluoromethyl-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;
- N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-β-(4-oxo-2,3-dihydro-[1,5]-
- 30 benzoxazepin-5-yl)propionylamino]propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;
- N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;
- 35 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)butyramide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]-azepin-5-yl)propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

5 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]-azepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]thiazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]-thiazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,11-dioxo-5,11-dihydro-dibenzo[b,f][1,4]thiazepin-10-yl)pentanamide;

20 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,5,11-dioxo-5,11-dihydro-dibenzo[b,f][1,4]thiazepin-10-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

25 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-chloro-5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,12-dioxo-6,6a,7,8,9,10-hexahydro-12H-benzo[e]pyrido[1,2-a][1,4]diazepine-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(9-fluoro-2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;

30 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]-thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

35 N-[1(R)-(3-amino-2(S)-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxy-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;

N-[1(R)-(3-amino-2(R)-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butanamide;

N-[1(R)-(3-Amino-2-hydroxy-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(1,1,4-trioxo-benzo-[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-[1,5]benzothiazepin-5-yl)propionamide;


N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-3,4-dihydro[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-cyano-5-isopropyl-2-oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrol-1-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10-yl)propionamide and

N-[1(R)-[2-Hydroxy-3-(2(R)-hydroxypropylamino)propylcarbamoyl]-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide.

The compounds of the instant invention all have at least one asymmetric centers as noted by the asterisk in the structural Formula I a. Additional asymmetric centers may be present on the molecule depending on the nature of the various substituents on the molecule.



I a

As consequence of these chiral centers, the compounds of the present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as

separated, pure or partially purified optical isomers or racemic mixtures thereof, be included within the ambit of the instant invention.

The term "R" and "S" are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center. The term "R" (rectus) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priorities group. The term "S" (sinister) refers to that configuration of a chiral center with a counterclockwise relationship of a group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The priority of groups is based on their atomic number (in order of decreasing atomic number).

In the case of the asymmetric center represented by the asterisk in Formula I a, it has been found that the compound in which the B substituent is below the plane of the structure, as seen in Formula I a, is more active and thus more preferred over the compound in which the B substituent is above the plane of the structure.

This invention encompasses the pharmaceutically acceptable salts of the compounds defined by Formula I. A compound of this invention can possess a sufficiently acidic, a sufficient basic, or both functional groups, and accordingly react with any of a number of organic or inorganic acids, and organic or inorganic bases, to form a pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" as used herein, refers to salts of the compounds of above Formula I which are substantially non-toxic to live organism. Typically pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with pharmaceutically acceptable mineral or organic acid or an organic or inorganic base. Such salts are acid addition and base addition.

The instant compounds are generally isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids. Examples of such inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid, and the like. Examples of such organic acids include acetic acid, trifluoroacetic acid, propionic acid, maleic acid, succinic acid, maleic acid, oxalic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like. Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids as methanesulfonic acid, trifluoroacetic acid, maleic acid.

The instant compounds are also generally isolated in the form of their pharmaceutically acceptable base addition salts, such as salts derived from using inorganic and organic bases. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate,

calcium carbonate, and the like. The sodium and potassium salts are particularly preferred.

It should be recognized that the particular counterion forming a part of any salt of this invention is usually not of a critical nature, so long as the salt as a whole is pharmaceutically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.

This invention further encompasses the pharmaceutically acceptable solvates of the compounds of Formula I. Most compounds of the Formula I can be combined with solvents such as water, methanol, ethanol, and acetonitrile to form pharmaceutically acceptable solvates such as corresponding hydrate, metanolate, ethanolate, and acetonitrilate.

Throughout the instant application the following abbreviations are used with the following meanings :

BOC : t-butoxycarbonyl

15 BOP : benzotriazole-1-yloxy-tris-(dimethylamino)- phosphonium-hexafluorophosphate

CBZ : benzyloxycarbonyl

DCC : dicyclohexyl carbodiimide

DMF : N,N-dimethylformamide

20 EDC : 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

FAB-MASS : FAB Mass Spectrum

Fmoc : 9-fluorenylmethoxycarbonyl

HOBt : 1-hydroxybenzotriazole

MHz : Megahertz

25 NMM : N-Methylmorpholine

NMR : Nuclear Magnetic Resonance


Ser : Serine

Nal : Naphthylalanine


TFA : trifluoroacetic acid

30 The preparation of compounds of Formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses detailing the preparation of the compounds of Formula I in a sequential manner are presented in the following Schemes 1,2, and 3.

The compounds having a Formula I are prepared from intermediates such as 1.




Typical intermediates 3 may be synthesized as shown in Scheme 1. Ester derivatives 2 are, in some cases, commercially available or are prepared by a number of methods well known in the art. Coupling of intermediate 1 with ester derivative 2 is carried out by standard peptide coupling reaction conditions using an acid activating agent such as EDC, DCC, and BOP in an inert solvent such as dichloromethane or DMF, with or without the presence of a catalyst such as HOBt. The skills required in carrying out the reaction and purification of the resulting reaction products are known to those in the art. Purification procedure includes crystallization, and / or chromatography.




Conversion of typical intermediates 3 to intermediate acids 4 may be accomplished by a number of methods known in the art described in Scheme 2; for example, methyl and ethyl esters can be hydrolyzed with sodium hydroxide, potassium hydroxide, or lithium hydroxide in a protic solvent like aqueous methanol, ethanol, dioxane. In addition, removal of benzyl ester can be achieved by a number of reductive methods including hydrogenation in the presence of palladium catalyst in a protic solvent such as methanol. An allyl ester can be cleaved with tetrakis-triphenylphosphine palladium catalyst in the presence of 2-ethylhexanoic acid in a variety of solvents including

ethyl acetate and dichloromethane. t-Butyl ester can be removed with acid like hydrogen chloride, TFA in a various solvents including dioxane and dichloromethane.




Scheme 2

Diamino derivatives 5,6 are either commercially available or can be synthesized by routine methods. Compounds of Formula I and intermediates 7 are synthesized in following Scheme 3. Coupling a carboxylic acid 4 with an amine 5 or 6 is carried out using acid activating agent such as EDC, DCC, and BOP in a solvent such as dichloromethane or DMF with or without the presence of such as HOBT. Purification



of the resulting reaction products are known to those in the art. Purification procedure includes crystallization, and / or chromatography using as a carrier like a silica gel.

The preparation of compounds of Formula I and intermediate 7 may also be carried out in convergent synthetic route illustrated in Scheme 4,5,6,7. The protected amino acid derivatives 8 are, in some cases, commercially available, where the protecting L^1 is, for example, BOG or CBZ or Fmoc groups. Other protected amino acid derivatives 8 can be prepared by a number of methods well known in the literature. Intermediate 9 or 10 are prepared by coupling of protecting amino acids derivatives 8 with diamino derivatives 5 or 6.




Scheme 4

Conversion of 9, 10 to intermediate 11, 12 can be achieved as shown in Scheme 5 by removal of the protecting group L^1 (CBZ, BOC, Fmoc, Formyl, Phthaloyl, etc.). CBZ and BOC are used extensively in the synthesis, and their removal conditions are known to those skilled in the art. For example, removal of CBZ groups can be carried out by a number of methods known in the art; for example, catalytic hydrogenation with hydrogen in the presence of a novel metal or its oxide such as palladium on activated carbon in a protic solvent such as ethanol. In the cases where catalytic hydrogenation is contraindicated by the presence of other potentially reactive functionality, removal of CBZ groups can also be achieved by treatment with a solution of hydrogen bromide in acetic acid, or by treatment with a mixture of TFA and dimethylsulfide. Removal of BOC protecting groups is carried out in a solvent such as ethyl acetate or dioxane or methylene chloride or methanol, with a strong acids, such as TFA or hydrochloric acid or hydrogen chloride gas. Removal of Fmoc groups is carried out with an organic base such as dimethylamine or piperazine. Removal of formyl groups is carried out in a solvent such as water or methanol with an acid such as hydrochloric acid or hydrazine-acetic acid. Deprotection of phthaloyl groups is

achieved in a solvent such as methanol or ethanol or dioxane with hydrazine.

Conditions required to remove other protecting groups which may be present and can be found in Green, T. and Wuts, P.G.M., Protective Group in Organic Synthesis, John Wiley & Sons, Inc., New York, NY 1991. It should be recognized that L is different from


- 5 L¹ and is stable to the removal conditions of L¹. For example, when L¹ is CBZ or Fmoc, BOC as L is preferred.



The u:
reatm


Scheme 5

Compounds of Formula I in present invention and intermediates 7 are synthesized as shown in Scheme 6. Coupling a carboxylic acid 1 with an amine 11 or 12 is achieved using a condition described above.



Scheme 6

Conversion of intermediates 7 to compounds of Formula I may be accomplished as illustrated in Scheme 7. Removal of protecting group L may be carried out by various conditions described above.



Scheme 7

The growth hormone releasing compounds of Formula I are useful in vitro as unique tools for understanding how growth hormone secretion is regulated at the pituitary levels. This includes use in the evaluation of many factors thought or known to influence growth hormone secretion such as age, sex, nutritional factors, glucose, amino acids, fatty acids, as well as fasting and non-fasting states. In addition, the compounds of this invention can be used in the evaluation of how other hormones modify growth hormone releasing activity. For example, it has already been established that somatostatin inhibits growth hormone release and that the growth hormone releasing factor (GRF) stimulates its release. Other hormones that are important and in need of study as to their effect on growth hormone release include the gonadal hormones, e.g., testosterone, estradiol, and progesterone; the adrenal hormones, e.g., cortisol and other corticoids, epinephrine and norepinephrine; the pancreatic and gastrointestinal hormones, e.g., insulin, glucagon, gastrin, secretin; the vasoactive peptides, e.g., bombesin, the neurokinins; and the thyroid hormones, e.g., thyroxine and triiodothyronine. The compounds of the Formula I can also be employed to investigate the possible negative or positive feedback effects of some the pituitary hormones, e.g., growth hormone and endorphin peptides, on the pituitary to modify growth hormone release. Of particular scientific importance is the use of these compounds to elucidate the subcellular mechanisms mediating the release of growth hormone.

The compounds of Formula I can be administered to animals, including man, to release growth hormone in vivo. For example, the compounds can be administered to commercially important animals such as swine, sheep, cow and the like to accelerate and increase their rate and extent of growth, to improve feed efficiency and to increase milk production in such animals. In addition, these compounds can be administered to humans in vivo as a diagnostic tool to directly determine whether the hypothalamus-pituitary system is capable of releasing growth hormone. For example, the compounds of Formula I can be administered to humans. Serum samples taken before and after such administration can be assayed for growth hormone. Comparison of the amounts of growth hormone in each of these samples would be a means for directly determining the ability of the patient's hypothalamus-pituitary system to release growth hormone.

Accordingly, the present invention includes within its scope pharmaceutical comprising, as an active ingredient, at least one of the compounds of Formula I in association with a pharmaceutical carrier or diluent. Optionally, the active ingredient of the pharmaceutical composition can comprise an anabolic agent in addition to at least one of the compounds of Formula I or another composition which exhibits a different activity, an antibiotic growth permittant or an agent to treat osteoporosis or in combination with a corticosteroid to minimized the catabolic side

effects or with other pharmaceutically active materials wherein the combination enhances efficiency and minimizes side effects.

Growth promoting and anabolic agents include, but are not limited to, THR, diethylstilbestrol, amino acids, estrogens, β -agonists, theophylline, anabolic
5 steroids, enkephalins, E series prostaglandins, retinoic acid, compounds disclosed in US Patent No.3,239,345, e.g., zeranol, and compounds disclosed in US Patent No. 4,036,979, e.g., sulbenox, or peptides disclosed in US Patent No.4,411,890.

A still further use of the compounds of this invention is in combination with other growth hormone secretagogues such as the growth hormone releasing peptides
10 GHRP-6, GHRP-1 as described in US Patent No.4,411,890 and publications WO 89/07110, WO89/07111 and B-HT920 as well as hexarelin and GHRP-2 as described in WO 93/04081 or growth hormone releasing hormone (GHRH also designated GRF) and its analogs or growth hormone and its analogs or somatomedins including IGF-1 and IGF-2 or α -adrenergic agonists such as clonidine or serotonin 5HT_{1D} agonists
15 such as sumatriptan or agents which inhibit somatostatin or its release such as physostigmine and pyridostigmine. In particular, the compounds of this invention may be used in combination with growth hormone releasing factor, an analog of growth hormone releasing factor, IGF-1, or IGF-2. For example, a compound of the present invention may be used in combination with IGF-1 for the treatment or prevention of
20 obesity. In addition, a compounds of this invention may be employed in conjunction with retinoic acid to improve the condition of musculature and skin that results from intrinsic agents.

The present invention is further directed to a method for the manufacture of a medicament for stimulating the release of growth hormone in humans and animals
25 comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.

As is well known to those skilled in the art, the known and potential uses of growth hormone are varied and multitudinous. Thus, the administration of the compounds of this invention for purpose of stimulation the release of endogenous growth hormone
30 can have the same effects or uses as growth hormone itself. These varied uses may be summarized as follows; stimulating growth hormone release in elderly humans; treating growth hormone deficient adults; prevention of catabolic side effects of glucocorticoids; treatment of osteoporosis; stimulation of the immune system, acceleration of wound healing; accelerating bone fracture repair; treatment of growth
35 retardation; treating acute or chronic renal failure or insufficiency; treatment of physiological short stature, including growth hormone deficient children; treating short stature associated with chronic illness; treating obesity and growth retardation associated with obesity; treating growth retardation associated with Prader-Willi

syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients or following major surgery such as gastrointestinal surgery; treatment of intrauterine growth retardation, and skeletal dysplasia; treatment of hypercortisonism and Cushing's syndrome; treatment of peripheral

5 neuopathies; replacement of growth hormone in stressed patients; treatment of osteochondrodysplasias, Noonans syndrome, sleep disorders, schizophrenia, depression, Alzheimer's disease, delayed wound healing, and psychosocial deprivation; treatment of pulmonary dysfunction and ventilator dependency; attenuation of protein catabolic response after a major operation; treating malabsorption syndrome; reducing

10 cachexia and protein loss due to chronic illness such as cancer or AIDS; accelerating weight gain and protein accretion in patients on TPN (total parenteral nutrition); treatment of hyperinsulinemia including nesidioblastosis; adjuvant treatment for ovulation induction and to prevent and treat gastric and duodenal ulcers; stimulation of thymic development and prevention of the age-related decline of thymic function;

15 adjunctive therapy for patients on chronic hemodialysis; treatment of immunosuppressed patients and to enhanced antibody response following vaccination; increasing the total lymphocyte count of a human, in particular, increasing the T4/T8-cell ratio in a human with a depressed T4/T8-cell ratio resulting, for example, from infection, such as bacterial or viral infection, especially infection with the

20 human immunodeficiency virus; treatment of syndromes manifested by non-restorative sleep and musculoskeletal pain, including fibromyalgia syndrome or chronic fatigue syndrome; improvement in muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis in the frail elderly; stimulation of osteoblasts, bone remodeling, and cartilage growth; treatment of male and female infertility;

25 stimulation of the immune system in companion animals and treatment of disorders of aging in companion animals; growth promotant in livestock; and stimulation of wool growth in sheep. Further, the instant compounds are useful for increasing feed efficiency, promoting growth, increasing milk production and improving the carcass quality of livestock. Likewise, the instant compounds are useful in a method of

30 treatment of diseases or conditions which are benefited by the anabolic effects of enhanced growth hormone levels that comprises the administration of an instant compound.

In particular, the instant compounds are useful in the prevention or treatment of a condition selected from the group consisting of; osteoporosis; catabolic illness; immune

35 deficiency, including that in individuals with a depressed T4/T8-cell ratio; hip fracture; musculoskeletal impairment in the elderly; growth hormone deficiency in adults or in children; obesity; sleep disorders; cachexia and protein loss due to chronic illness such as AIDS or cancer; and treating patients recovering from major surgery,

wounds or burns, in a patient in need thereof.

In addition, the instant compounds may be useful in the treatment of illness induced or facilitated by corticotropin releasing factor or stress- and anxiety-related disorders, including stress-induced depression, and headache, abdominal bowel syndrome, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal disease, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems.

It will be known to those skilled in the art that there are numerous compounds now being used in an effort to treat the diseases or therapeutic indications enumerated above. Combinations of these therapeutic agents some of which have also been mentioned above with the growth hormone secretagogues of this invention will bring additional complementary, and often synergistic properties to enhance the growth promotant, anabolic and desirable properties of these various therapeutic agents. In these combinations, the therapeutic agents and the growth hormone secretagogues of this invention may independently present in dose ranges from one one-hundredth to one times the dose levels which are effective when these compounds and secretagogues are used singly.

Combined therapy to inhibit bone resorption, prevent osteoporosis and enhance the healing of bone fractures can be illustrated by combinations of bisphosphonates and the growth hormone secretagogues of this invention. The use of bisphosphonates for these utilities has been reviewed, for example, by Hamdy, N.A.T., "Role of Bisphosphonates in Metabolic Bone Diseases" Trends in Endocrinol. Metab., 4, 19-25 (1993). Bisphosphonates with these utilities include alendronate, tiludronate, diethyl-APD, risedronate, etidronate, YM-175, clodronate, pamidronate, and BM-210995. Accordingly to their potency, oral daily dosage levels of the bisphosphonate of between 0.1 mg and 5 g and daily dosage levels of the growth hormone secretagogues of this invention of between 0.01 mg/kg to 20 mg/kg of body weight are administered to patients to obtain effective treatment of osteoporosis.

In the case of alendronate daily oral dosage levels of 0.1 mg to 50 mg are combined for effective osteoporosis therapy with 0.01 mg/kg to 20 mg/kg of the growth hormone secretagogues of this invention.

Combined therapy to enhance the healing of bone fractures, wounds or burns can be illustrated by combinations of growth factors, especially bFGF (basic fibroblast growth factor), and the growth hormone secretagogues of this invention (Canalis, E. Clin. Orthop., 1985, 193, 246-263; Kawaguchi, H. Endocrinology, 1994, 135, 774-781; Nakamura, T. et al., Endocrinology, 1995, 136, 1276-1284; Shida, J. et al., Journal of Orthopaedic Research, 1996, 14, 265-272).

Combined therapy to enhance the healing of bone fractures, wounds or burns can

also be illustrated by combinations of growth factors, especially PDGF(platelet-derived growth factor), and the growth hormone secretagogues of this invention(Stile,C.D. et al., Proc.Natl.Acad.Sci.USA,1979, 76, 1279-1283; Chen,Y. et al., J.Cell Physol.,1989, 140, 59-67).

- 5 Osteoporosis and other bone disorders may also be treated with compounds of this invention in combination with calcitonin, estrogen, raloxifene and calcium supplements such as calcium citrate or calcium carbonate.

Anabolic effects especially in the treatment of geriatric male patients are obtained with compounds of this invention in combination with anabolic steroids such as
10 oxymetholone, methyltestosterone, fluoxymesterone and stanozolol.

Other uses of the instant compounds will be apparent from the following references; Amato, et al., Journal of Clinical Endocrinology and Metabolism 77(6):1671-1676 (1993),

Bengtsson, et al., Journal of Clinical Endocrinology and Metabolism 76(2):309-317
15 (1993),

Binnerts, et al., Clinical Endocrinology 37:79-87(1992);

Bowers, et al., Journal of Clinical Endocrinology and Metabolism 76(4):817-823(1993),

Cuneo, et al., Journal of Applied Physiology 70(2):688-694(1991),

Cuneo, et al., Journal of Applied Physiology 70(2):695-700(1991),

20 Degerblad, et al., Acta Endocrinologica 126:387-393(1992),

Eden, et al., Arteriosclerosis and Thrombosis 13:296-301(1993),

Hartman, et al., Horm Research 40:37-47(1993),

Ho, et al., Horm Research 40:80-86(1993),

Jorgensen, et al., Acta Endocrinologica 125:449-453(1991),

25 Jorgensen, et al., The Lancet June 3:1221-1224(1989),

Lambert, et al., Clinical Endocrinology 37:111-115(1992),

McGauley, et al., Horm Research 33:52-54(1990),

Moller,et al., Clinical Endocrinology 39:403-408(1993),

O'Halloran, et al., Journal of Clinical Endocrinology and Metabolism 76(5):1344-1348
30 (1993),

Orme, et al., Clinical Endocrinology 37:453-459(1992),

Rodriguez-Amao, et al., Horm Research 39:87-88(1993),

Rosen, et al., Clinical Endocrinology 40:111-116(1994),

Rosen, et al., Acta Endocrinologica 129:195-200(1993),

35 Rudman, et al., The New England Journal of Medicine 323(1):1-6(1990),

Salmon, et al., The New England Journal of Medicine 321(26):1797-1803(1989),

Shibasaki, et al., Journal of Clinical Endocrinology and Metabolism 58(1):212-214 (1984),

Sonksen, *et al.*, Acta Paediatr Scand [Suppl]379:139-146(1991),

Tauber, *et al.*, Journal of Clinical Endocrinology and Metabolism 76(5):1135-1139 (1993),

Vandeweghe, *et al.*, Clinical Endocrinology 39:409-415(1993),

5 Whitehead, *et al.*, Clinical Endocrinology 36:45-52(1992),

Bercu, *et al.*, U.S.patent No. 5,246,920.

Additionally, the most potent compounds of this invention can be used as GH antagonists. It is known that hypothalamic hormones that are super agonists can also used as antagonists. For example super agonists of Gonadotropin Releasing Hormone (GnRH) such as Gonadorelin and Leuprolide act either as agonists or antagonists depending on the method of administration. The action of the GnRH super agonists are summarized in Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ED., McGraw Hill Inc., p.1353(1993). By analogy, it is believed the continuous administration of the compounds of formula I will lead to down-regulation of the growth response. These molecules can therefore be used as functional

agonists of pituitary GH secretion, thereby antagonizing GH or IGF-1.

Uses of such antagonists of GH secretion include but are not limited to;

treatment of excess GH secretion as in acromegaly or gigantism; in cancer of the breast, colon and prostate; in diabetes especially in Type I adolescent patients to

20 counteract the dawn phenomenon; and Type I and Type II patients to directly control blood glucose, and to control the long-term effects of diabetes, as for example in retinopathy.

The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection or

25 infusion, or implant), nasal, pulmonary, vaginal, rectal, sublingual, or topical routes of administration and can be formulated in dosage forms appropriate for each route of administration.

Accordingly, the present invention includes within its scope for pharmaceutical composition comprising, as active ingredient, at least one of the compounds of

30 Formula I in association with a pharmaceutical acceptable carrier. Optionally, the active ingredient of the pharmaceutical compositions can comprise an anabolic agent in addition to at least one of the compounds of formula I or another composition which exhibits a different activity, e.g., an antibiotic growth permittant or an agent to treat osteoporosis or in combination with a corticosteroid to minimize the catabolic side effects or with a growth factor such as bFGF (basic fibroblast growth factor) for

35 treatment of patients recovering from major surgery, bone fractures, wounds, burns or with other pharmaceutically active materials wherein the combination enhances

efficacy and minimizes side effects.

The compounds of this invention can be administered by oral, parenteral (e.g., intraperitoneal, intramuscular, intravenous, or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or other topical routes of administration and can be formulated with pharmaceutically acceptable carries to provide appropriate dosage forms for each route of administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solids dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tables and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsion, solutions, suspensions, syrups, the elixirs coating inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvent or vehicles are propylene glycol,

Composition for nasal or sublingual administration are also prepared with standard excipients well known in the art.

The dosage of active ingredient in the compositions of this invention may be varied, however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effects, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 0.0001 to 100 mg/kg of body weight daily are administered to patients and animals, e.g., to obtain effective release of GH.

A preferred dosage range is 0.01 to 10.0 mg/kg of body weight daily.

Examples

[Example 1] (Sequential method)

N-[1 (R) -(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo- 2,3,-dihydro-[1,5]-benzothiazepin-5-yl)propionamide hydrochloride

Step 1:

[3-(2(R)-Amino-3-naphthalen-2-yl-propionylamino)propyl]carbamic acid, tert-butyl ester

To DMF(15ml) solution of CBZ-D-Nal-OH(1.1g) and N-(3-Aminopropyl) carbamic acid tert-butyl ester (500mg), HOBt(530mg), EDC(720mg) were added under cooling on ice-water and then stirring was continued at room temperature overnight. The reaction mixture was poured into saturated sodium hydrogen carbonate solution (150ml), formed precipitate was collected by filtration and then dried to give white powder(1.43g). Obtained white powder(1.43g) in DMF(15ml) is hydrogenated with 10% Pd-C(400mg) at 35°C, 4.3 atm. for 4 days. After removal of catalyst by filtration, filtrate was evaporated to dryness and then crystallized from n-hexane:ethyl acetate. The crystal was collected and then dried to afford 640mg of product.

¹H-NMR(270MHz, CDCl₃) δ : 1.34(2H,s), 1.43(9H,s), 1.59(2H,m), 2.90(1H,dd),
3.05(2H,q), 3.32(2H,q), 3.41(1H,dd), 3.70(1H,bs),
5.02(1H,bs), 7.38(1H,d), 4.40-7.55(3H,m), 7.66(1H,s),
7.75-7.85(3H,m)

FAB-MSS : m/z 370(M+H)⁺

Step 2:

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)propionamide hydrochloride

To DMF(2ml) solution of 3-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)- propionic acid(100mg) and [3-(2(R)-Amino-3-naphthalen-2-yl-propionylamino)- propyl]-carbamic acid,t-butyl ester(134mg), EDC(90mg) and HOBt(66mg) were added under cooling on ice-water and then stirring was continued at room temperature overnight. The reaction mixture was poured into saturated sodium hydrogen carbonate solution(20ml), formed precipitate was collected by filtration and then dried to give white powder(217mg). After obtained white powder(80mg) was dissolved in ethyl acetate(2ml) under cooling on ice-water, 4N hydrogen chloride/ethyl acetate solution was added and then stirring is continued at room temperature for three hours. The reaction mixture was concentrated under reduced pressure. Ether was added to the oily residue. Solidified oily residue was collected by filtration and then dried to give 69mg of product.

¹H-NMR(270MHz, DMSO-d₆) δ : 1.30-1.65(2H,m), 2.00-2.20(2H,m), 2.20-2.45(2H,m),
2.70-3.00(3H,m), 3.00-3.60(6H,m), 3.98(1H,bs),
4.51(1H,m), 7.25(1H,t), 7.35-7.65(6H,m), 7.66-
8.05(6H,m),

8.17(1H,d),8.25(1H,t)

FAB-MSS : m/z 505(M+H)⁺

Compounds of Example 2~147,164~166,169,171,174,175,177,179,187~190, 193~196,199~273 were synthesized by using similar method of Example 1.

5 Compounds of Example 34~37,40~45,102~103,112,136~137,177 were free base and NMR were measured in CDCl₃.

Compounds of Example 2~33,38~39,46~101,104~111,113~135,138~147,164,176, 179,187~190,193~196,199~273 were hydrochloride salts and NMR were measured in DMSO-d₆.

10 [Example 148] (Convergent method)

N-[1(R)-(2-Amino-ethylcarbamoyl)-2-benzyloxyethyl]-3-(4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl)propionamide hydrochloride

Step 1:

15 3-Benzyloxy-2-[3-(4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl)propionylamino]propionic acid methyl ester

To DMF(2ml) solution of D-Ser(Bzl)-OMe hydrochloride(141mg) and 3-(4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl)-propionic acid(138mg),N-methyl morpholine(61mg), HOBT(92mg) and EDC(125mg) were added under cooling on ice-water and then stirring is continued at room temperature overnight. After reaction, reaction mixture was poured into saturated sodium hydrogen carbonate solution(20ml) and then extracted with ethyl acetate. Ethyl acetate layer was dried on anhydrous sodium sulfate and then evaporated to dryness. Title compound(270mg) was isolated by using silica gel chromatography(CHCl₃:MeOH=100:1).

25 ¹H-NMR(270MHz,CDCl₃) δ : 2.35-2.60(3H,m),2.65-2.80(1H,m),3.20-3.40(2H,m),
3.45-3.90(3H,m),3.71(3H,s),4.49(3H,m),4.64(1H,d),
6.56(1H,d),7.15-7.50(8H,m),7.59(1H,d)

FAB-MSS : m/z 443(M+H)⁺

Step 2:

30 N-[1(R)-(2-Amino-ethylcarbamoyl)-2-benzyloxyethyl]-3-(4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl)propionamide hydrochloride

To amethylalcohol solution(5ml) of 3-Benzyloxy-2-[3-(4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl)propionylamino]propionic acid methyl ester(260mg),1N sodium

hydroxy solution(0.62ml) was added under cooling on ice-water and the stirring was continued for 3 hours. Reaction mixture is adjusted to pH 2 with 1N hydrochloric acid and then evaporated to dryness. To residue, water is added, extracted with ethyl acetate and then dried on anhydrous sodium sulfate. Ethyl acetate was removed by evaporation to give oily residue(210mg). To DMF solution of above oily residue and N-(2-aminoethyl)carbamic acid tert-butyl ester(79mg), HOBt(92mg) and EDC (120mg) were added under cooling on ice-water and then stirring was continued at room temperature overnight. Reaction mixture was poured into saturated sodium hydrogen carbonate solution(40ml), formed precipitate was collected by filtration and then dissolved in ethyl acetate, dried on anhydrous sodium sulfate. After removal ethyl acetate by evaporation, white powder(180mg) was isolated by using silica gel chromatography (CHCl₃:MeOH=100:1). Hydrogen chloride salt of desired product was prepared as following way. To ethyl acetate solution(2ml) of obtained white powder (70mg), 4N hydrogen chloride ethyl acetate-solution(2ml) was added under cooling on ice-water and then stirring was continued at room temperature for 3 hours. After removal of solvent by evaporation, ether was added to oily residue. Solidified oily residue was collected by filtration and then dried to give 48mg of product.

¹H-NMR(270MHz, DMSO-d₆) δ : 2.20-2.65(4H,m), 2.70-2.90(2H,m), 3.20-3.75(7H,m), 4.15-4.55(4H,m), 7.20-7.40(6H,m), 7.50-7.75(3H,m), 7.95(2H,bs), 8.10-8.25(2H,m)

FAB-MSS : m/z 471(M+H)⁺

Compounds of Example 149~163, 167, 168, 170, 172, 173, 176, 178, 180~186, 191, 192, 197, 198 were synthesized by using similar method of example 148.

Compounds of Example 168, 180 were free base and NMR were measured in CDCl₃.

Compounds of Example 149~163, 167, 170, 172, 173, 176, 178, 181~186, 191, 192, 197, 198 were hydrochloride salts and NMR were measured in DMSO-d₆.

[Test Example]

Compounds of Formula I were evaluated in vitro for their efficacy and potency to release growth hormone(GH) in primary rat anterior pituitary cells. Preparation of rat primary anterior pituitary cells were be essentially same as described previously (Chen et al., Endocrinology, 1989, 124, 2791- 2798 and Chen et al., Endocrinology, 1991, 129, 3337-3342). Briefly, Rats were killed by decapitation. The pituitary was quickly removed. The anterior pituitaries were digested with 0.2% collagenase, 0.2% hyaluronidase and 200U/ml DNase I in Hank's balanced salt solution. The cells were

resuspended in Dulbecco's Modified Eagle's medium containing 7.5% horse serum ,
5.0% fetal calf serum, 1% nonessential amino acids, 100 U/ml penicillin and 100 μ g/ml
streptomycin and adjusted to 1.0×10^5 cells/ml. 0.5 ml of this suspension was placed
in each well of 48 -well trays and left for 3 days before release experiments were
5 performed.


On day of the experiments, cells were washed twice with the above medium
containing 20mM HEPES, pH7.4. Growth hormone release was initiated by addition of
medium containing 20mM HEPES and test compound. Incubation was carried out for
15 minutes at 37°C. After incubation, GH release into the medium was measured by
10 a standard radioimmunoassay (RIA) procedure.

Compounds of Example number 1,9,10,14,15,19,64,68,79,94,96,107,112, 115,121,
126, 129,134,135,140,144,145,159,160,164,165,181,182,200,205,206,212,216,236,241,
242,244,249,252, ,253,254,255,257,258,259,262,263,264 have shown growth hormone
15 (GH) releasing activity below 10^{-8} M.

Evaluation of GH-releasing activity by oral administration in rats were carried out
as follows.


Male Sprague-Dawley rats (4 weeks old, n=6 per group) were fasted overnight and
test compounds (10mg/kg) were orally administered. Thirty minutes after the
20 administration the rats were decapitated and the trunk blood was collected in a
heparin-containing tube. After centrifugation, the plasma was stored at -20°C before
the GH assay by RIA as described above. Plasma GH values were converted into
logarithms and the analysis of variance (ANOVA) was performed. The significance of
the difference was examined by the LSD method.

25 Compound of Example number 165,206,253,257,259,262,264 have shown plasma
GH value above 10 ng/ml.














Example number	o	q	¹ H-NMR(δ ppm) :	FAB-MS(M+H) ⁺
2	1	2	2.30-2.45(2H,m),2.80-3.50(8H,m),3.55-4.10(1H,m),4.68(2H,bs),7.17(1H,bs),7.40-7.60(5H,m),7.65-8.10(7H,m),8.30-8.50(2H,m)	477
3	1	3	1.60-1.80(2H,m),2.30-2.55(2H,m),2.60-4.20(9H,m),4.66(2H,bs),7.16(1H,bs),7.35-7.60(6H,m),7.65-8.00(7H,m),8.25(1H,bs),8.41(1H,bs)	491
4	1	4	1.30-1.65(4H,m),2.30-2.55(2H,m),2.60-2.80(2H,m),2.90-4.15(7H,m),4.50-4.80(2H,m),7.16(1H,bs),7.35-7.6(5H,m),7.65-8.00(7H,m),8.16(1H,bs),8.40(1H,bs)	505
5	2	2	2.05-2.45(3H,m),2.75-3.00(3H,m),3.10-3.65(6H,m),3.90-4.25(1H,m),4.50(1H,dd),7.26(1H,t),7.35-7.55(5H,m),7.58(1H,d),7.69(1H,s),7.75-7.95(3H,m),8.07(2H,bs),8.25-8.40(2H,m)	491
6	2	4	1.30-1.55(4H,m),2.00-2.55(4H,m),2.60-2.75(2H,m),2.80-4.30(8H,m),4.49(1H,dd),7.26(1H,t),7.30-7.65(5H,m),7.65-7.90(7H,m),8.03(1H,t),8.24(1H,d)	519
7	2	5	1.10-1.40(4H,m),1.40-1.60(2H,m),2.00-3.65(13H,m),3.90-4.25(1H,m),4.48(1H,dd),7.26(1H,t),7.30-7.55(5H,m),7.58(1H,d),7.67(1H,d),7.70-8.00(6H,m),8.22(1H,d)	533
8	2	6	1.00-1.60(8H,m),2.00-3.65(13H,m),3.90-4.25(1H,m),4.48(1H,dd),7.15-8.00(14H,m),8.21(1H,d)	547
9	3	2	1.30-1.65(2H,m),2.00-2.20(2H,m),2.20-2.45(2H,m),2.70-3.00(3H,m),3.00-3.60(6H,m),3.98(1H,bs),4.51(1H,dd),7.25(1H,t),7.35-7.65(6H,m),7.65-8.05(6H,m),8.17(1H,d),8.25(1H,t)	505
10	3	3	1.30-1.75(4H,m),2.00-2.15(2H,m),2.20-2.45(2H,m),2.60-2.80(2H,m),2.89(1H,dd),3.05-3.45(6H,m),3.95(1H,bs),4.50(1H,dd),7.28(1H,t),7.30-7.65(6H,m),7.65-7.95(6H,m),8.10-8.20(2H,m)	519
11	3	4	1.30-1.70(6H,m),1.95-2.15(2H,m),2.20-2.50(2H,m),2.60-2.80(2H,m),2.80-3.45(7H,m),3.85-4.10(1H,m),4.52(1H,dd),7.24(1H,t),7.30-7.55(5H,m),7.58(1H,d),7.65-7.95(6H,m),8.00-8.20(2H,m)	533
12	3	5	1.10-1.65(8H,m),1.95-2.15(2H,m),2.20-2.45(2H,m),2.55-2.80(2H,m),2.85-3.50(7H,m),3.80-4.10(1H,m),4.40-4.60(1H,m),7.24(1H,t),7.30-7.50(5H,m),7.58(1H,d),7.65-7.90(6H,m),7.95(1H,t),8.09(1H,d)	547


Example number	o	q	$^1\text{H-NMR}(\delta \text{ ppm})$:	FAB-MS(M+H) ⁺
13	3	6	1.00-1.60(10H,m),1.95-2.15(2H,m),2.20-2.50(2H,m),2.60-2.85(2H,m), 2.85-3.55(7H,m),3.80-4.10(1H,m),4.51(1H,dd),7.15-8.00(14H,m),8.08 (1H,d)	561
14	4	2	1.05-1.40(4H,m),1.85-2.10(2H,m),2.20-2.45(2H,m),2.70-3.00(3H,m), 3.05-3.40(4H,m),3.50-3.80(2H,m),3.85-4.10(1H,m),4.52(1H,dd),7.25 (1H,s),7.30-7.65((6H,m),7.65-8.00(6H,m),8.10(1H,d),8.21(1H,t)	519
15	4	3	1.00-1.50(4H,m),1.55-1.80(2H,m),1.90-2.10(2H,m),2.25-2.45(2H,m), 2.60-2.80(2H,m),2.91(1H,dd),3.00-3.50(6H,m),3.85-4.10(1H,m),4.51 (1H,dd),7.25(1H,t),7.30-7.65(6H,m),7.65-7.95(5H,m),8.00-8.25(2H,m)	533













Example number	o	D	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
16	1		2.35-2.60(5H,m),3.85-3.10(3H,m),3.10-3.50(5H,m),3.55-4.05(1H,m),4.70(2H,bs),7.16(1H,bs),7.40-7.60(5H,m),7.65-7.95(5H,m),8.20-8.55(2H,m),8.80(2H,bs)	491
17	2		2.00-2.65(7H,m),2.75-3.00(3H,m),3.10-3.60(6H,m),3.90-4.25(1H,m),4.49(1H,dd),7.27(1H,t),7.30-7.65(6H,m),7.65-7.90(4H,m),8.20-8.35(1H,m),8.75(2H,bs)	505
18	1		1.60-1.80(2H,m),2.35-2.60(5H,m),2.70-3.45(8H,m),3.45-4.20(1H,m),4.65(2H,bs),7.15(1H,bs),7.40-7.60(5H,m),7.72(1H,s),7.75-7.95(4H,m),8.25(1H,bs),8.42(1H,bs),8.63(2H,bs)	505
19	2		1.55-1.75(2H,m),2.00-2.65(7H,m),2.65-2.80(2H,m),2.89(1H,dd),3.00-3.60(6H,m),3.95-4.40(1H,m),4.46(1H,dd),7.26(1H,t),7.35-7.65(6H,m),7.65-7.90(4H,m),8.15(1H,t),8.28(1H,d),8.59(2H,bs)	519
20	3		1.30-1.85(4H,m),1.95-2.20(2H,m),2.20-3.00(7H,m),3.00-3.70(6H,m),4.00(1H,bs),4.49(1H,bs),7.15-8.00(11H,m),8.17(2H,bs),8.56(2H,bs)	533
21	1		1.25(6H,s),2.35-2.50(2H,m),2.85-3.45(6H,m),3.55-4.20(1H,m),4.71(2H,bs),7.27(1H,t),7.35-7.60(6H,m),7.65-8.10(7H,m),8.36(1H,φ)	505
22	2		1.15(6H,s),2.05-2.60(4H,m),2.80-3.00(2H,m),3.05-3.80(5H,m),3.95-4.40(1H,bs),4.49(1H,dd),7.20-7.30(1H,m),7.35-7.60(6H,m),7.65-8.00(7H,m),8.26(1H,d)	519



Example number	o	D	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
23	2		0.75(3H,s),0.80(3H,s),2.00-2.65(6H,m),2.85-3.00(3H,m),3.00-3.60(4H,m),4.10(1H,bs),4.53(1H,dd),7.26(1H,t),7.35-7.60(6H,m),7.65-7.90(6H,m),8.25-8.45(2H,m)	533
24	3		0.75(3H,s),0.80(3H,s),1.30-1.70(2H,m),2.00-2.20(2H,m),2.20-2.60(4H,m),2.85-3.05(3H,m),3.05-3.50(4H,m),3.90-4.10(1H,m),4.55(1H,dd),7.24(1H,t),7.35-7.56(6H,m),7.65-7.95(6H,m),8.19(1H,d),8.36(1H,t)	547
25	2		1.55(2H,m),2.00-2.60(4H,m),2.60-4.30(14H,m),4.85(1H,dd),7.28(1H,t),7.35-7.55(5H,m),7.60(1H,d),7.65-8.20(9H,m)	548
26	3		1.30-1.90(4H,m),2.00-2.15(2H,m),2.20-2.50(2H,m),2.50-4.15(14H,m),4.86(1H,dd),7.25(1H,t),7.30-7.55(4H,m),7.59(1H,d),7.65-8.20(9H,m)	562
27	2		1.60-1.95(4H,m),2.00-2.55(4H,m),2.60-2.85(3H,m),2.85-3.60(10H,m),3.95-4.25(1H,m),4.85(1H,dd),7.28(1H,t),7.35-7.55(5H,m),7.60(1H,d),7.65-8.10(6H,m),8.50(1H,d)	562
28	3		1.30-1.65(2H,m),1.65-1.95(4H,m),2.00-2.15(2H,m),2.20-2.50(2H,m),2.60-2.85(3H,m),2.85-3.45(10H,m),3.99(1H,bs),4.87(1H,dd),7.25(1H,t),7.35-7.55(5H,m),7.59(1H,d),7.70-8.10(6H,m),8.37(1H,d)	576
29	2		2.00-2.60(4H,m),2.89(1H,dd),3.05-3.60(6H,m),3.65-3.80(2H,m),3.90-4.25(1H,m),4.50(1H,dd),5.45-5.60(2H,m),7.24(1H,t),7.35-7.55(5H,m),7.58(1H,d),7.67(1H,s),7.75-7.90(3H,m),8.01(2H,bs),8.20-8.35(2H,m)	517
30	3		1.30-1.60(2H,m),1.95-2.15(2H,m),2.20-2.50(2H,m),2.90(1H,dd),3.05-3.60(6H,m),3.05-4.10(3H,m),4.51(1H,dd),5.40-5.65(2H,m),7.24(1H,t),7.30-7.50(5H,m),7.58(1H,d),7.65-8.05(6H,m),8.12(1H,d),8.27(1H,t)	531
31	2		1.20-1.50(2H,m),1.75-1.95(2H,m),2.00-2.60(4H,m),2.75-3.60(8H,m),3.90-4.40(3H,bs),4.97(1H,dd),7.20-7.90(11H,m),8.00-8.20(2H,m),8.41(1H,dd)	531
32	2		2.10-2.65(4H,m),2.80-3.80(13H,m),4.10(1H,bs),4.95(1H,dd),7.27(1H,t),7.35-7.65(6H,m),7.65-7.85(4H,m)	517
33	2		1.50-1.90(2H,m),1.90-2.70(6H,m),2.75-3.00(2H,m),3.0-3.60(5H,m),3.90-4.35(2H,m),4.48(1H,dd),7.20-7.90(11H,m),8.20-8.50(2H,m),9.12(1H,bs)	517


Exempl number	o	D	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
34	1		1.70-2.65(10H,m),3.05-3.50(6H,m),4.05-4.40(1H,m),4.45-4.70(1H,m),4.75-4.95(1H,m),7.05-7.90(13H,m)	505
35	2		1.85(6H,s),1.90-2.05(1H,m),2.10-2.20(1H,m),2.30-2.75(4H,m),3.00-3.40(6H,m),3.60-3.80(1H,m),4.40-4.65(2H,m),7.15-7.50(6H,m),7.55-7.70(2H,m),7.70-7.85(3H,m)	519
36	2		1.40-1.65(2H,m),1.90-2.80(12H,m),3.00-3.40(6H,m),3.55-3.80(1H,m),4.35-4.65(2H,m),6.60-6.80(1H,m),7.05-7.85(12H,m)	533
37	3		1.35-1.95(4H,m),2.05-2.70(10H,m),2.85-3.60(9H,m),3.95-4.45(1H,m),4.60-4.80(1H,m),7.00-7.90(13H,m)	547
38	1		1.45(2H,bs),2.15-2.80(7H,m),3.05-3.50(6H,m),4.00-4.95(3H,m),7.05-7.85(11H,m)	491
39	2		1.35(2H,bs),2.10(2H,d),2.30-2.75(7H,m),2.95-3.45(6H,m),3.55-3.80(1H,m),4.40-4.70(2H,m),7.15-7.50(6H,m),7.5-7.85(5H,m)	505
40	1		1.35-1.75(4H,m),2.30-3.50(13H,m),4.15-4.75(2H,m),5.10-5.40(1H,m),7.10-7.90(12H,m)	505
41	2		1.20-1.75(4H,m),2.25-2.75(9H,m),2.90-3.45(6H,m),3.60-3.80(1H,m),4.40-4.60(1H,m),5.05-5.25(1H,m),6.70-6.90(1H,m),7.15-7.50(6H,m),7.50-7.85(5H,m)	519
42	3		1.30-2.75(14H,m),2.75-3.55(8H,m),4.20-4.55(1H,m),5.10-5.35(1H,m),6.85-7.5(7H,m),7.55-7.90(5H,m)	533
43	1		0.90(3H,s),1.05(3H,s),2.25-2.65(4H,m),2.95-3.50(6H,m),4.05-4.60(2H,m),4.75-5.00(1H,m),7.00-7.85(13H,m)	505
44	2		0.85(3H,s),0.90(3H,s),1.85(2H,bs),2.30-2.70(4H,m),2.95-3.40(6H,m),3.55-3.75(1H,m),4.35-4.60(1H,m),4.65-4.80(1H,dd),7.15-7.50(6H,m),7.55(1H,d),7.65-7.85(4H,m)	519
45	2		1.05-1.55(4H,m),2.35-2.80(5H,m),2.90-2.85(9H,m),4.45-4.65(1H,m),4.75-4.95(1H,m),6.80-6.95(1H,m),7.15-8.50(11H,m)	517




Example number	o	q	*	J	¹ H-NMR (δ ppm) :	FAB-MS (M+H) ⁺
46	1	2	(S)		2.35-2.45(2H,m), 2.80-3.50(8H,m), 3.55-4.10(1H,m), 4.69(1H,bs), 7.16(1H,bs), 7.40-7.60(5H,m), 7.65-8.10(7H,m), 8.30-8.50(2H,m)	477
47	2	2	(S)		2.05-2.60(4H,m), 2.70-2.95(3H,m), 3.10-3.60(6H,m), 3.85-4.25(1H,m), 4.47(1H,dd), 7.26(1H,t), 7.30-7.50(5H,m), 7.58(1H,d), 7.60-8.00(6H,m), 8.15-8.35(2H,m)	491
48	2	3	(S)		1.55-1.75(2H,m), 2.00-2.95(7H,m), 3.00-3.65(6H,m), 3.90-4.35(1H,m), 4.46(1H,dd), 7.20-7.65(7H,m), 7.65-7.95(6H,m), 8.15(1H,t), 8.27(1H,d)	505
49	3	3	(S)		1.30-1.75(4H,m), 1.90-2.15(2H,m), 2.20-2.45(2H,m), 2.65-2.80(2H,m), 2.91(1H,dd), 3.00-3.55(6H,m), 3.85-4.10(1H,m), 4.49(1H,dd), 7.15-7.65(7H,m), 7.65-7.95(6H,m), 8.05-8.25(2H,m)	519
50	1	2	(R)		2.35-2.55(2H,m), 2.75-2.95(3H,m), 3.09(1H,dd), 3.20-3.50(4H,m), 3.55-4.15(1H,m), 4.56(2H,bs), 7.15-7.35(7H,m), 7.35-7.45(1H,m), 7.58(1H,d), 7.99(2H,bs), 8.20-8.45(2H,m)	427
51	2	2	(R)		2.10-2.45(4H,m), 2.65-2.85(3H,m), 2.85-3.85(6H,m), 4.10(1H,bs), 4.38(1H,dd), 7.10-7.35(6H,m), 7.40-7.65(3H,m), 8.10-8.25(2H,m)	441
52	1	2	(S)		2.35-2.50(2H,m), 2.70-2.95(3H,m), 3.09(1H,dd), 3.15-3.50(4H,m), 3.60-4.10(2H,m), 4.57(2H,bs), 7.15-7.30(7H,m), 7.35-7.45(1H,m), 7.59(1H,d), 7.97(2H,bs), 8.20-8.45(2H,m)	427
53	2	2	(S)		2.10-2.45(4H,m), 2.65-2.85(3H,m), 2.85-3.85(6H,m), 4.10(1H,bs), 4.38(1H,dd), 7.10-7.35(6H,m), 7.40-7.65(3H,m), 8.10-8.25(2H,m)	441
54	3	2	(S)		1.35-1.65(2H,m), 1.95-2.20(2H,m), 2.25-2.50(2H,m), 2.70-2.90(3H,m), 3.02(1H,dd), 3.85-4.15(1H,m), 4.40(1H,d), 7.05-7.30(6H,m), 7.35-7.55(2H,m), 7.61(1H,d), 7.86(2H,bs), 8.05-8.25(2H,m)	455

Example number	o	q	*	J	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
55	2	2	(R)		2.05-2.60(4H,m),2.75-2.95(3H,m),3.00-3.70(6H,m),4.15(1H,bs), 4.39(1H,dd),6.90-7.15(3H,m),7.25-7.35(2H,m),7.45-7.65(4H,m), 7.88(2H,bs),8.05-8.20(2H,m),10.80(1H,s)	480
56	2	3	(R)		1.55-1.70(2H,m),2.00-2.60(4H,m),2.60-2.75(2H,m),2.87(1H,dd), 2.95-3.15(3H,m),3.15-3.65(3H,m),3.95-4.30(1H,m),4.37(1H,dd), 6.85-7.10(3H,m),7.20-7.35(2H,m),7.40-7.65(4H,m),7.82(2H,bs), 8.00-8.20(2H,m),10.80(1H,s)	494
57	3	2	(R)		1.35-1.70(2H,m),2.00-2.25(2H,m),2.25-2.50(2H,m),2.70-3.00(3H, m),3.00-3.60(6H,m),3.90-4.20(1H,m),4.42(1H,dd),6.90-7.15(3H, m),7.20-7.65(6H,m),7.75-8.10(3H,m),8.16(1H,t),10.80(1H,s)	494
58	3	3	(R)		1.35-1.75(4H,m),2.05-2.20(2H,m),2.30-2.45(2H,m),2.60-2.80(2H, m),2.91(1H,dd),3.00-3.15(3H,m),3.15-3.55(3H,m),3.95-4.15(1H, m),4.36(1H,dd),6.90-7.15(3H,m),7.20-7.65(6H,m),7.80(2H,bs), 8.01(1H,d),8.11(1H,t),10.81(1H,s)	508
59	1	2	(S)		2.35-2.45(2H,m),2.70-3.50(8H,m),3.60-4.20(1H,m),4.58(2H,bs), 6.90-7.45(7H,m),7.57(2H,t),7.98(3H,bs),8.20-8.40(2H,m),10.86 (1H,s)	466
60	2	3	(R)		1.55-1.75(2H,m),2.00-2.80(6H,m),3.00-3.70(7H,m),3.90-4.30(1H, m),4.49(1H,dd),7.20-7.65(9H,m),7.70-8.00(4H,m),8.05-8.25(2H, m),8.25-8.40(1H,m)	505
61	3	3	(R)		1.30-1.75(4H,m),1.95-2.20(2H,m),2.25-2.50(2H,m),2.60-2.80(2H, m),3.05-3.80(7H,m),3.90-4.10(1H,m),4.51(1H,dd),7.20-7.65(9H, m),7.65-8.00(4H,m),8.05-8.25(3H,m)	519
62	3	3	(R)		1.35-1.55(2H,m),1.65-1.80(2H,m),2.00-2.20(2H,m),2.25-2.45(2H, m),3.10-3.50(6H,m),3.67(1H,dd),3.80-4.10(1H,m),4.81(1H,dd), 7.25(1H,t),7.35-7.50(1H,m),7.58(1H,d),7.75-8.10(6H,m),8.15- 8.45(4H,m),8.75-8.95(1H,m)	520
63	2	3	(R)		1.60-1.75(6H,m),2.10-2.90(12H,m),3.05-3.35(4H,m),3.40-3.65 (1H,m),3.95-4.10(1H,m),4.10-4.35(2H,m),6.85(3H,d),7.25-7.30 (1H,m),7.45-7.50(2H,m),7.60(1H,d),7.80(3H,bs),8.05(1H,t),8.15 (1H,d)	509
64	3	3	(R)		1.45-1.80(10H,m),2.15(2H,bs),2.45(2H,bs),2.65-3.00(8H,m),3.15 -3.25(2H,m),3.25-3.40(1H,m),4.10(1H,bs),4.35-4.45(1H,m),6.95 (3H,bs),7.35(2H,t),7.55(2H,bs),7.70(1H,d),7.98(2H,bs),8.15(1H, d),8.25(1H,t)	523


Exempl number	o	q	*	J	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
65	2	3	(RS)		1.55-1.70(2H,m),2.10-2.50(4H,m),2.65-2.85(4H,m),2.95-3.15(4H,m),3.30-3.40(1H,m),4.00-4.10(1H,m),4.35-4.45(1H,m),7.00-7.05(2H,m),7.20-7.30(2H,m),7.35-7.65(6H,m),7.80(3H,bs),8.10(1H,t),8.25(1H,d),9.50(1H,bs)	521
66	3	3	(RS)		1.40-1.55(2H,m),1.60-1.70(2H,m),2.00-2.10(2H,m),2.00-2.10(2H,m),2.25-2.40(2H,m),2.65-2.90(4H,m),3.00-3.15(4H,m),3.35-3.45(1H,m),3.90-4.00(1H,m),4.35-4.45(1H,m),7.00-7.05(2H,m),7.20-7.25(2H,m),7.45(1H,bs),7.50-7.65(4H,m),7.75(3H,bs),8.05-8.15(2H,m),9.50(1H,bs)	535




Example number	o	q	¹ H-NMR(δ ppm) :	FAB-MS(M+H) ⁺
67	3	2	1.30-1.55(2H,m),1.95-2.15(2H,m),2.25-2.45(2H,m),2.75-3.00(3H,m),3.10-3.45(3H,m),3.50-4.25(4H,m),4.52(1H,dd),7.30-8.10(13H,m),8.10-8.35(2H,m)	521
68	3	3	1.30-1.55(2H,m),1.55-1.75(2H,m),1.95-2.10(2H,m),2.25-2.45(2H,m),2.60-2.80(2H,m),2.85-3.25(4H,m),3.25-4.20(4H,m),4.49(1H,dd),7.30-7.95(13H,m),8.05-8.25(2H,m)	535



Exempl number	o	q	*	J	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
69	1	2	(R)		2.35-2.70(2H,m), 2.80-4.20(9H,m), 4.50-4.85(2H,m), 7.10-8.15(13H,m), 8.25-8.50(1H,m), 8.60(1H,d)	509
70	2	2	(R)		2.05-2.60(4H,m), 2.70-3.00(3H,m), 3.00-4.20(7H,m), 4.49(1H,dd), 7.35-7.60(7H,m), 7.60-7.95(6H,m), 8.31(2H,bs)	523
	3	2	(R)		1.35-1.70(2H,m), 2.00-2.10(2H,m), 2.45-2.55(2H,m), 2.65-3.00(3H,m), 3.05-3.50(5H,m), 3.60-3.90(2H,m), 4.53(1H,dd), 7.35-7.55(5H,m), 7.65-8.00(8H,m), 8.17(1H,d), 8.26(1H,t)	537
72	3	3	(R)		1.30-1.80(4H,m), 1.95-2.15(2H,m), 2.40-2.60(2H,m), 2.60-2.80(2H,m), 2.91(1H,dd), 3.00-3.20(4H,m), 3.45-3.95(3H,m), 4.51(1H,dd), 7.30-7.55(5H,m), 7.65-7.95(8H,m), 8.05-8.25(2H,m)	551
73	1	2	(R)		2.35-2.55(1H,m), 2.55-2.65(1H,m), 2.70-2.95(3H,m), 3.11(1H,dd), 3.20-3.45(3H,m), 3.50-4.15(2H,m), 4.25-4.85(2H,m), 7.27(6H,s), 7.50-7.65(1H,m), 7.75(1H,t), 7.90(1H,d), 7.98(2H,bs), 8.26(1H,bs), 8.52(1H,d)	459
74	2	2	(R)		2.05-2.60(4H,m), 2.70-2.85(2H,m), 3.02(1H,dd), 3.10-3.45(3H,m), 3.55-4.25(3H,m), 4.38(1H,dd), 7.10-7.30(5H,m), 7.56(1H,t), 7.67(1H,d), 7.80-8.10(4H,m), 8.15-8.30(2H,m)	473
75	1	2	(S)		2.35-2.55(1H,m), 2.55-2.70(1H,m), 2.70-2.95(3H,m), 3.12(1H,dd), 3.20-3.45(3H,m), 3.50-4.20(2H,m), 4.25-4.85(2H,m), 7.27(6H,s), 7.45-7.60(1H,m), 7.75(1H,t), 7.89(1H,d), 7.96(2H,bs), 8.26(1H,bs), 8.53(1H,d)	459
76	2	2	(S)		2.05-2.60(4H,m), 2.70-2.85(2H,m), 3.02(1H,dd), 3.10-3.45(3H,m), 3.55-4.25(3H,m), 4.38(1H,dd), 7.10-7.30(5H,m), 7.56(1H,t), 7.67(1H,d), 7.80-8.10(4H,m), 8.15-8.30(2H,m)	473
77	3	2	(S)		1.40-1.75(2H,m), 1.95-2.15(2H,m), 2.30-2.60(2H,m), 2.70-2.90(3H,m), 3.00(1H,dd), 3.15-4.30(6H,m), 4.40(1H,dd), 7.05-7.25(5H,m), 7.45-7.80(3H,m), 7.80-8.00(3H,m), 8.05-8.25(2H,m)	487
78	3	3	(R)		1.45-1.75(4H,m), 2.00-2.15(2H,m), 2.40-2.60(2H,m), 2.60-2.75(2H,m), 2.89(1H,dd), 3.00-3.15(3H,m), 3.25-3.95(4H,m), 4.41(1H,dd), 6.90-7.15(3H,m), 7.31(1H,d), 7.45-7.60(3H,m), 7.65-7.95(4H,m), 8.01(1H,d), 8.10(1H,t), 10.80(1H,s)	540




Example number	o	q	R ¹³	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
79	2	3	CH ₃	1.15(2H,d),1.35(1H,d),1.65(2H,t),1.80-2.30(2H,m),2.48(2H,m),2.71(2H,t),2.90(1H,m),3.12(3H,m),3.25-4.30(3H,m),4.45(1H,m),7.20-7.60(7H,m),7.65-8.00(6H,m),8.15(1H,m),8.27(1H,m)	519
80	3	2	CH ₃	1.17(2H,m),1.25-1.60(3H,m),1.85-2.25(3H,m),2.45(1H,m),2.60-3.05(3H,m),3.05-3.45(3H,m),3.60-4.10(3H,m),4.52(1H,m),7.00-7.60(7H,m),7.65-7.90(4H,m),8.00-8.30(3H,m),8.34(1H,bs)	519
81	3	3	CH ₃	1.18(2H,m),1.25-1.60(3H,m),1.69(2H,t),1.90-2.35(3H,m),2.50(1H,m),2.73(2H,m),2.90(1H,m),3.17(3H,m),3.30-4.10(3H,m),4.50(1H,m),7.00-7.60(7H,m),7.65-7.90(4H,m),7.96(2H,bs),8.10-8.30(2H,m)	533
82	2	3		1.65(2H,t),2.15(1H,m),2.35-3.00(5H,m),3.10(3H,m),3.25-3.65(2H,m),4.00-4.30(1H,m),4.47(1H,m),4.89(1H,m),6.10(1H,s),6.34(1H,s),7.20-7.60(8H,m),7.65-7.95(6H,m),8.16(1H,bs),8.29(1H,t)	571




Example number	o	q	R ¹⁴	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
83	2	2	7-CF ₃	2.05-2.60(4H,m),2.70-2.95(3H,m),3.10-3.70(6H,m),3.90-4.25(1H,m),4.49(1H,dd),7.30-7.50(3H,m),7.60(1H,d),7.62(1H,s),7.70-8.10(7H,m),8.20-8.35(2H,m)	559
84	3	2	7-CF ₃	1.30-1.60(2H,m),1.95-2.20(2H,m),2.25-2.50(2H,m),2.70-3.00(3H,m),3.15-3.60(6H,m),3.75-4.15(1H,m),4.51(1H,dd),7.30-7.50(3H,m),7.59(1H,d),7.65-8.10(8H,m),8.16(1H,d),8.25(1H,t)	573


Example number	o	q	R ¹²	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
85	2	3	7-CF ₃	1.50-1.75(2H,m),2.05-2.80(6H,m),2.88(1H,dd),3.00-3.20(3H,m),3.20-3.70(3H,m),3.95-4.35(1H,m),4.46(1H,dd),7.30-7.50(3H,m),7.60(1H,d),7.67(1H,s),7.70-7.95(7H,m),8.14(1H,t),8.26(1H,d)	573
86	3	3	7-CF ₃	1.30-1.75(4H,m),1.95-2.15(2H,m),2.25-2.50(2H,m),2.65-2.80(2H,m),2.91(1H,dd),3.00-3.50(6H,m),3.80-4.15(1H,m),4.50(1H,dd),7.30-7.50(3H,m),7.58(1H,d),7.65-7.95(9H,m),8.05-8.25(2H,m)	587
87	2	4	7-CF ₃	1.25-1.55(4H,m),2.00-2.60(4H,m),2.60-2.80(2H,m),2.80-3.80(7H,m),3.85-4.25(1H,m),4.40-4.60(1H,m),7.25-7.95(12H,m),8.03(1H,t),8.23(1H,d)	587
88	3	4	7-CF ₃	1.25-1.60(6H,m),2.05(2H,t),2.25-2.55(2H,m),2.60-2.80(2H,m),2.80-3.50(7H,m),3.95(1H,bs),4.45-4.60(1H,m),7.30-7.95(12H,m),8.00-8.15(2H,m)	601
89	2	2	8-F	2.00-2.65(4H,m),2.70-3.00(3H,m),3.10-3.65(6H,m),3.85-4.25(1H,m),4.40-4.60(1H,m),7.20-7.55(5H,m),7.65-8.10(6H,m),8.15-8.35(2H,m)	509
90	3	2	8-F	1.25-1.60(2H,m),1.95-2.20(2H,m),2.25-2.55(2H,m),2.70-3.70(9H,m),3.85-4.10(1H,m),4.40-4.60(1H,m),7.20-7.50(5H,m),7.65-8.10(7H,m),8.17(1H,d),8.26(1H,t)	523
91	2	3	8-F	1.55-1.75(2H,m),2.00-2.55(4H,m),2.55-2.80(2H,m),2.89(1H,dd),3.00-3.60(6H,m),3.90-4.35(1H,m),4.35-4.55(1H,m),7.20-7.50(5H,m),7.65-7.95(6H,m),8.15(1H,t),8.26(1H,d)	523
92	3	3	8-F	1.25-1.80(4H,m),1.95-2.15(2H,m),2.20-2.50(2H,m),2.60-2.80(2H,m),2.92(1H,dd),3.00-3.65(6H,m),3.85-4.10(1H,m),4.40-4.60(1H,m),7.20-7.55(5H,m),7.60-8.00(7H,m),8.05-8.25(2H,m)	537




Example number	o	q	J	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
93	2	2		1.85-2.10(4H,m),2.30(2H,m),2.70-2.95(3H,m),3.10-3.40(3H,m),3.75-3.95(2H,bs),4.50(1H,dd),7.10-7.55(7H,m),7.68(1H,s),7.75-8.10(5H,m),8.20-8.30(2H,m)	473
94	2	3		1.65(2H,m),1.90-2.10(4H,m),2.30(2H,m),2.65-2.75(2H,m),2.86(1H,dd)3.05-3.15(3H,m),3.70-3.90((2H,bs),4.44(1H,dd),7.10-7.50(7H,m),7.68(1H,s),7.75-7.95((5H,m),8.16(1H,t),8.27(1H,d)	487
95	2	2		2.05(4H,m),2.32(2H,m),2.58(2H,m),2.76(2H,m),2.84(1H,dd),3.09(1H,dd),3.26(2H,m),3.85(2H,bs),4.38(1H,m),6.90-7.40(8H,m),7.53(1H,d),7.89(2H,bs),8.16(2H,m),10.89(1H,s)	462




Example number	o	q	J	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
96	2	3		1.65(2H,m),2.03(2H,m),2.30(2H,m),2.70(2H,m),2.89(1H,dd),3.10(3H,m),3.78(3H,s),4.45(1H,dd),7.87(2H,d),7.22(1H,t),7.38(1H,d),7.46(2H,m),7.68(1H,s),7.75-7.95(5H,m),8.16(1H,t),8.26(1H,d)	517
97	3	3		1.45(2H,m),1.59(2H,m),2.01(6H,m),2.72(2H,m),2.90(1H,dd),3.14(3H,m),3.80(3H,s),4.50(1H,m),6.73(1H,bs),6.87(1H,d),7.19(1H,t),7.35-7.55 (3H,m),7.69(1H,s),7.75-7.95(5H,m),8.21(2H,m)	531
98	2	3		1.60-1.80(6H,m),1.90-2.10(4H,m),2.30(2H,bs),2.55-2.85(7H,m),3.05-3.15(2H,m),3.80(3H,s),4.25(1H,dd),6.85-6.95(5H,m),7.25(1H,t),7.80(3H,bs),8.05-8.15(2H,m)	521




Exempl number	o	q	R ¹⁴	R ¹⁵	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
99	2	3	8-OMe	H	1.65(2H,m),1.80-2.15(4H,m),2.31(2H,m),2.70(2H,t),2.87(1H,dd),3.10(3H,m),3.74(3H,s),3.85(2H,bs),6.75(1H,d),6.86(1H,s),7.10(1H,d),7.38(1H,d),7.46(2H,m),7.68(1H,s),7.70-7.95(5H,m),8.15(1H,t),8.26(1H,d)	517
100	3	3	6-Me	8-Me	1.46(2H,bs),1.68(2H,m),2.02(4H,m),2.22(3H,s),2.25(3H,s),2.73(2H,m),2.91(1H,dd),3.12(3H,m),4.51(1H,m),6.87(2H,s),7.43(3H,m),7.70(1H,s),7.75-7.95(5H,m),8.20(2H,m)	529




Example number	R ¹⁶	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
101	H	1.79(3H,s),1.85-2.70(4H,m),2.70-2.95(3H,m),3.10-3.35(3H,m),4.14(2H,m),4.46(1H,m),7.15-7.55(7H,m),7.67(1H,s),7.70-8.00(5H,m),8.10(1H,d),8.23(1H,m),8.28(1H,m)	530
102		1.18(3H,t),1.90(3H,s),2.20-3.50(13H,m),3.85-4.45(5H,m),7.05-7.40(5H,m),7.47(2H,m),7.63(1H,s),7.77(3H,m)	602




Example number	$^1\text{H-NMR}$ (δ ppm) :	FAB-MS ($\text{M}+\text{H}$) $^+$
103	1.26(3H,t), 1.90-2.35(6H,m), 2.40-2.80(5H,m), 3.00-3.20(3H,m), 4.94(1H,m), 6.64(1H,d), 7.00-7.40(5H,m), 7.45(2H,m), 7.67(1H,s), 7.75(3H,m)	571




Example number	o	q	¹ H-NMR(δ ppm) :	FAB-MS(M+H) ⁺
104	2	2	2.20-2.35(2H,m),2.44(2H,t),2.70-3.00(3H,m),3.10-3.35(3H,m),3.60-3.90(2H,m),4.35-4.55(3H,m),7.05-7.25(3H,m),7.30-7.50(4H,m),3.68(1H,s),7.70-8.00(5H,m),8.23(1H,t),8.30(1H,d)	475
105	2	3	1.55-1.75(2H,m),2.20-2.35(2H,m),2.43(2H,t),2.60-2.80(2H,m),2.89(1H,dd),3.00-3.20(3H,m),3.60-3.90(2H,m),4.35-4.55(3H,m),7.05-7.25(3H,m),7.30-7.50(4H,m),7.68(1H,s),7.70-7.95(5H,m),8.15(1H,t),8.29(1H,d)	489
106	3	2	1.35-1.55(2H,m),1.95-2.20(2H,m),2.40-2.55(2H,m),2.75-3.00(3H,m),3.15-3.45(3H,m),3.50-3.70(2H,m),4.35-4.60(3H,m),7.05-7.25(4H,m),7.35-7.50(3H,m),7.69(1H,s),7.75-8.05(5H,m),8.15-8.30(2H,m)	489
107	3	3	1.35-1.55(2H,m),1.55-1.75(2H,m),2.40-2.55(2H,m),2.65-2.80(2H,m),2.92(1H,dd),3.05-3.20(3H,m),3.45-3.75(2H,m),4.40-4.55(3H,m),7.05-7.25(4H,m),7.35-7.50(3H,m),7.70(1H,s),7.75-7.90(5H,m),8.10-8.25(2H,m)	503




Exempl enumber	o	q	A¹	¹H-NMR(δ ppm)	FAB-MS (M+H)⁺
108	2	3		1.64(2H,m),2.27(2H,t),2.42(1H,bs),2.73(2H,m),2.40(1H,dd),3.00(3H,m),5.40(1H,m),3.73(1H,m),4.04(1H,m),4.20(1H,m),4.43(1H,dd),7.30-7.60(6H,m),7.65-7.95(7H,m),8.15(1H,t),8.30(1H,d)	542
109	2	4		1.39(4H,m),2.29(2H,m),2.68(2H,m),2.89(1H,m),3.06(3H,m),3.09(3H,s),3.55-3.80(2H,m),3.90-4.25(2H,m),4.49(1H,m),7.25-7.60(6H,m),7.60-7.90(7H,m),8.01(1H,bs),8.25(1H,t)	530
110	2	3		1.09(3H,m),1.75(4H,m),2.10-2.65(3H,m),2.81(4H,m),3.00-3.40(3H,m),4.00-4.40(2H,m),4.53(1H,m),7.20-7.55(9H,m),7.65-7.90(6H,m)	545
111	2	2		2.45(2H,m),2.78(2H,m),2.90(1H,dd),3.15(1H,dd),3.28(2H,m),3.74(2H,m),4.53(1H,dd),7.09(2H,m),7.35-7.55(4H,m),7.59(1H,t),7.68(1H,s),7.78(3H,m),8.02(2H,bs),8.31(1H,t),8.48(1H,t)	459
112	2	3		1.28(2H,m),2.42(2H,m),2.67(2H,m),3.15(4H,m),4.15(2H,m),4.62(1H,dd),6.51(1H,d),6.87(3H,m),6.96(2H,t),7.10-7.25(5H,m),7.40-7.55(3H,m),7.68-7.85(3H,m)	525
113	3	3		1.50-1.85(6H,m),2.10(2H,m),2.55-2.80(3H,m),2.80-3.20(7H,m),4.58(1H,m),6.59(2H,m),6.89(2H,m),7.44(3H,m),7.60-8.00(6H,m),8.28(2H,m)	473




Exempl number	o	q	*	J	¹ H-NMR(DMSO-d ₆) δ :	FAB-MS (M+H) ⁺
114	2	2	(R)		1.20(1H,m), 1.51(1H,m), 1.73(2H,m), 2.25-3.00(9H,m), 3.10-3.50(4H,m), 4.15(1H,m), 4.47(1H,m), 7.27(4H,m), 7.35-7.55(3H,m), 7.69(1H,s), 7.75-8.10(5H,m), 8.27(2H,m)	487
115	2	3	(R)		1.20(1H,m), 1.35-2.65(11H,m), 2.70(2H,m), 2.88(1H,m), 3.10(3H,m), 4.15(1H,m), 4.45(1H,m), 7.25(4H,m), 7.35-7.55(3H,m), 7.69(1H,s), 7.75-7.95(5H,m), 8.17(1H,t), 8.27(1H,d)	501
116	2	3	(RS)		1.55-1.80(4H,m), 1.95-2.20(4H,m), 2.30-2.45(1H,m), 2.55-2.85(5H,m), 2.95-3.15(4H,m), 3.30-3.45(1H,m), 4.10-4.20(1H,m), 4.35-4.45(1H,m), 7.00-7.05(2H,m), 7.20-7.30(5H,m), 7.55-7.60(2H,m), 7.65(1H,d), 7.80(3H,bs), 8.10(1H,t), 8.25(1H,d), 9.50(1H,s)	517




Example number	o	q	X	K	¹ H-NMR(DMSO-d ₆) δ :	FAB-MS (M+H) ⁺
117	2	2	CH ₂	CH	2.30-2.55(4H,m),2.80(4H,m),2.95(1H,dd),2.95(1H,dd),3.25(1H,dd),3.88(1H,m),3.96(1H,m),4.55(1H,dd),7.00(2H,m),7.18(2H,m),7.46(3H,m),7.72(1H,s),7.75-7.95(3H,m),8.00(2H,bs),8.30(1H,t),8.43(1H,d)	459
118	2	3	CH ₂	CH	1.68(2H,m),2.25-2.50(4H,m),2.77(4H,m),2.92(1H,dd),3.13(3H,m),3.87(1H,m),3.97(1H,m),4.56(1H,dd),7.08(2H,m),7.18(2H,m),7.45(3H,m),7.72(1H,s),7.75-7.95(5H,m),8.22(1H,t),8.41(1H,d)	473
119	2	3	S	CH	1.64(2H,m),2.75(2H,m),2.94(1H,m),3.13(3H,m),3.90(1H,m),4.54(1H,m),7.04(1H,m),7.23(2H,m),7.35-7.50(4H,m),7.60-7.90(6H,m),8.32(1H,t),8.41(1H,d)	491
120	3	2	S	CH	1.58(2H,m),2.09(2H,m),2.82(2H,m),2.93(1H,dd),3.23(1H,dd),3.43(2H,s),3.53(1H,m),3.77(1H,m),4.58(1H,m),7.03(1H,t),7.19(2H,m),7.40(4H,m),7.72(4H,m),7.98(2H,bs),8.27(1H,d),8.32(1H,t)	491
121	3	3	S	CH	1.50-1.75(4H,m),2.10(2H,t),2.74(2H,m),2.91(1H,dd),3.13(3H,m),3.43(2H,s),3.52(1H,m),3.77(1H,m),4.57(1H,m),7.03(1H,t),7.10-7.25(2H,m),7.41(4H,m),7.65-7.95(6H,m),8.25(2H,m)	505
122	2	2	O	CH	2.41(2H,m),2.82(2H,m),2.94(1H,dd),3.22(1H,dd),3.87(1H,m),4.00(1H,m),4.54(1H,m),4.55(2H,s),6.99(3H,s),7.11(1H,d),7.35-7.50(3H,m),7.71(1H,s),7.82(3H,m),7.95(2H,bs),8.30(1H,t),8.49(1H,t)	461
123	2	3	O	CH	1.68(2H,m),2.41(2H,m),2.72(2H,m),2.91(1H,dd),3.13(3H,m),4.53(1H,m),4.57(2H,s),6.99(3H,m),7.13(1H,m),7.44(3H,m),7.72(1H,s),7.75-8.00(5H,m),8.24(1H,t),8.46(1H,d)	475
124	2	2	O	N	2.45(2H,m),2.81(2H,m),2.92(1H,dd),3.19(1H,dd),3.30(2H,m),4.12(2H,t),4.53(1H,dd),4.72(2H,s),7.03(3H,dd),7.38(1H,d),7.47(3H,m),7.72(1H,s),7.82(3H,m),7.97(1H,d),7.97(2H,bs),8.29(1H,t),8.37(1H,d)	462
125	2	3	O	N	1.67(2H,m),2.44(2H,m),2.72(2H,m),2.93(1H,dd),3.11(3H,m),4.12(2H,t),4.51(1H,m),4.72(2H,s),7.04(1H,dd),7.37(1H,d),7.47(3H,m),7.72(1H,s),7.75-7.95(5H,m),7.97(1H,d),8.22(1H,t),8.36(1H,d)	476




Example number	o	q	$^1\text{H-NMR}(\delta \text{ ppm}) :$	FAB-MS(M+H) ⁺
126	2	3	1.65(2H,m), 2.55(2H,m), 2.73(2H,m), 2.90(1H,dd), 3.10-3.20(3H,m), 4.10(2H,bs), 4.50(1H,dd), 7.20-7.65(9H,m), 7.65-7.90(7H,m), 8.20(1H,t), 8.39(1H,d)	537
127	3	3	1.67(4H,m), 2.11(2H,t), 2.75(2H,m), 2.90(1H,dd), 3.13(3H,m), 3.83(1H,m), 3.93(1H,m), 4.52(1H,m), 7.15-7.50(9H,m), 7.57(1H,t), 7.65-7.95(7H,m), 8.22(2H,m)	551













Example number	o	q	$^1\text{H-NMR}(\delta \text{ ppm}) :$	FAB-MS(M+H) ⁺
128	3	2	1.30-1.75(2H,m), 2.14(2H,t), 2.70-3.50(11H,m), 3.89(1H,m), 4.55(1H,m), 6.90-7.15(8H,m), 7.47(3H,m), 7.70-7.90(4H,m), 8.01(2H,bs), 8.30(2H,m)	549
129	3	3	1.45-1.75(4H,m), 2.13(2H,t), 2.65-3.35(10H,m), 3.89(1H,m), 4.54(1H,m), 6.90-7.15(8H,m), 7.47(3H,m), 7.70-7.95(6H,m), 8.24(2H,m)	563
130	4	3	1.15-1.50(4H,m), 1.66(2H,t), 2.08(2H,t), 2.71(2H,m), 2.91(3H,m), 3.52(1H,m), 3.91(1H,m), 4.53(1H,dd), 6.90-7.15(8H,m), 7.49(3H,m), 7.71(1H,s), 7.75-7.95(5H,m), 8.19(2H,m)	577
131	4	4	1.20-1.55(8H,m), 2.07(2H,t), 2.70(2H,m), 2.80-3.20(8H,m), 3.90(1H,m), 4.56(1H,dd), 6.96(1H,d), 7.07(7H,m), 7.45(3H,m), 7.70(1H,s), 7.75-7.90(5H,m), 8.07(1H,t), 8.13(1H,d)	591




Exempl enumber	o	q	*	J	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
132	2	3	(R)		1.60-1.75(6H,m),2.30-2.50(2H,m),2.60-2.90(10H,m),3.05-3.20(4H,m),3.50-3.60(1H,m),4.20-4.40(2H,m),6.85-7.15(1H,m),7.75-7.90(3H,bs),8.15(1H,t),8.25(1H,d)	553
133	2	3	(RS)		1.55-1.75(2H,m),2.30-2.50(2H,m),2.60-2.90(5H,m),2.90-3.20(5H,m),3.40-3.55(1H,m),4.20-4.30(1H,m),4.40-4.50(1H,m),6.90-7.20(10H,m),7.25-7.30(1H,m),7.55-7.65(3H,m),7.75(3H,bs),8.15(1H,t),8.30-8.35(1H,m),9.65(1H,s)	565




Exempl enumber	o	A'	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
134	2		2.00-2.70(5H,m),2.70-2.95(2H,m),3.00-3.60(6H,m),3.65-3.80(1H,m),3.73(1H,bs),4.50(1H,bs),5.54(1H,bs),7.26(1H,t),7.30-7.50(5H,m),7.57(1H,d),7.60-7.95(6H,m),8.15-8.35(2H,m)	521
135	3		1.25-1.60(2H,m),1.95-2.15(2H,m),2.15-2.70(3H,m),2.70-3.00(2H,m),3.00-3.45(6H,m),3.72(1H,bs),4.00(1H,bs),4.55(1H,dd),5.55(1H,bs),7.24(1H,t),7.30-7.50(5H,m),7.58(1H,d),7.65-7.95(6H,m),8.14(1H,d),8.23(1H,t)	535
136	2		1.95-2.70(4H,m),2.70-2.95(2H,m),3.00-3.55(7H,m),3.65-3.80(1H,m),3.85-4.25(1H,m),4.40-4.60(1H,m),7.20-7.50(6H,m),7.60-7.95(6H,m),8.10-8.35(2H,m),	539
137	3		1.25-1.60(2H,m),1.95-2.15(2H,m),2.25-2.60(4H,m),2.60-3.55(7H,m),3.65-3.80(1H,m),3.85-4.10(1H,m),4.53(1H,dd),7.20-7.50(6H,m),7.65-7.95(6H,m),8.13(1H,d),8.22(1H,t)	553


example number	o	A ¹	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
138	2		2.00-2.70(5H,m),2.70-2.95(2H,m),3.00-3.80(7H,m),3.90-4.35(1H,m),4.50(1H,bs),5.54(1H,bs),7.30-7.50(3H,m),7.59(1H,d),7.68(1H,s),7.70-8.00(7H,m),8.15-8.40(2H,m)	589
139	3		1.25-1.60(2H,m),1.90-2.15(2H,m),2.20-2.70(3H,m),2.70-3.50(8H,m),3.73(1H,bs),3.95(1H,bs),4.54(1H,dd),5.54(1H,d),7.30-7.95(12H,m),8.13(1H,d),8.23(1H,t)	603
140	2		1.85-2.10(4H,m),2.28(2H,bs),2.56(2H,m),2.70-2.95(2H,m),3.05-3.30(3H,m),3.73(2H,m),3.78(3H,s),4.50(1H,m),5.60(1H,bs),6.84(2H,m),7.22(1H,t),7.45-7.55(3H,m),7.69(1H,s),7.75-7.95(5H,m),8.25(2H,m)	533
141	3		1.44(2H,m),2.02(4H,m),2.40-3.85(12H,m),4.54(1H,m),6.73(1H,bs),6.86(1H,d),7.18(1H,t),7.46(3H,m),7.70-7.95(6H,m),8.20(1H,d),8.25(1H,t)	547
142	2		2.15-2.35(2H,m),2.43(2H,t),2.50-2.70(1H,m),2.70-2.95(2H,m),3.00-3.25(3H,m),3.60-3.90(3H,m),4.41(2H,t),4.45-4.60(1H,m),5.56(1H,bs),7.05-7.25(3H,m),7.25-7.35(1H,m),7.35-7.50(3H,m),7.69(1H,s),7.70-8.00(5H,m),8.23(1H,t),8.31(1H,d)	505
143	3		1.35-1.55(2H,m),1.90-2.10(2H,m),2.35-2.70(3H,m),2.70-3.00(2H,m),3.00-3.85(6H,m),4.35-4.60(3H,m),5.55(1H,bs),7.05-7.25(4H,m),7.35-7.50(3H,m),7.60-7.95(6H,m),8.17(1H,d),8.23(1H,t)	519
144	2		1.23(1H,m),1.50(1H,m),1.74(2H,m),1.95-3.60(15H,m),3.73(1H,m),4.12(1H,m),4.48(1H,m),5.54(1H,bs),7.24(4H,m),7.46(3H,m),7.70(1H,s),7.75-7.90(5H,m),8.25(2H,m)	517
145	2		2.55(2H,m),2.70-3.00(3H,m),3.15(3H,m),3.75(1H,m),4.06(2H,m),4.55(1H,m),7.15-7.50(10H,m),7.55-7.95(7H,m),8.25(1H,t),8.38(1H,m)	553
146	2		1.90(2H,m),2.25(2H,m),2.40-2.65(3H,m),2.70-2.95(2H,m),3.16(3H,m),3.41(1H,m),3.53(1H,m),3.71(2H,m),4.04(2H,m),4.16(1H,m),4.47(1H,m),5.53(1H,d),7.25-7.60(6H,m),7.65-7.95(7H,m),8.19(1H,t),8.26(1H,d)	558
147	2		2.40-2.70(2H,m),2.70-3.00(2H,m),3.05-3.45(4H,m),3.70-3.90(3H,m),4.64(1H,m),5.58(1H,bs),6.90(4H,m),7.11(4H,m),7.45(3H,m),7.73(1H,s),7.75-7.95(5H,m),8.31(1H,t),8.39(1H,d)	541




Example number	$^1\text{H-NMR}(\delta \text{ ppm}) :$	FAB-MS(M+H) $^+$
149	2.35-2.55(2H,m), 2.75-2.95(2H,m), 3.10-3.50(4H,m), 3.60-3.75(2H,m), 4.03(1H, bs), 4.45-4.90(4H,m), 7.2-7.5(8H,m), 7.59(1H,d), 7.94(2H,bs), 8.22(1H,t), 8.40(1H,d)	457




Example number	o	*	R ¹³	D	$^1\text{H-NMR}(\delta \text{ ppm}) :$	FAB-MS(M+H) $^+$
150	1	(S)	H		2.30-2.45(2H,m), 2.80-3.95(13H,m), 4.60(1H,bs), 5.10(1H, dd), 7.10-7.25(1H,m), 7.40-7.60(5H,m), 7.65-7.95(5H,m), 8.59(1H,bs), 9.25(1H,bs) 9.64(1H,bs)	503
151	2	(S)	H		2.30-2.60(4H,m), 2.80-3.80(12H,m), 4.10(1H,bs), 4.45(1H, bs), 4.95(1H,bs), 7.20-7.90(11H,m), 8.50(1H,d), 8.80(1H,bs)	517
152	2	(R)	CH ₃		1.14(2H,d), 1.32(1H,d), 1.80-3.55(11H,m), 3.55-4.20(3H,m), 4.49(1H,m), 5.55(1H,bs), 7.26(1H,m), 7.30-7.60(6H,m), 7.65-7.95(6H,m), 8.15-8.35(2H,m),	535
153	2	(R)	CH ₃		1.17(2H,d), 1.36(1H,d), 1.80-2.30(2H,m), 2.47(2H,m), 2.90(1H,m), 3.10(1H,m), 3.52(2H,m), 3.60-4.20(3H,m), 3.73(2H,m), 4.50(1H,m), 5.51(2H,m), 7.27(1H,m), 7.30-7.60(6H,m), 7.65-7.90(4H,m), 8.04(2H,bs), 8.27(2H,m)	531























Exempl number	o	D	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
154	2		1.30-1.50(4H,m),1.90-2.10(4H,m),2.30(2H,m),2.68(2H,m),2.86(1H,dd),3.07(3H,m),3.80(1H,bs),4.48(1H,dd),7.10-7.30(4H,m),7.30-7.50(3H,m),7.67(1H,s),7.75-7.90(5H,m),8.04(1H,t),8.23(1H,d)	501
155	2		2.01(4H,m),2.29(2H,m),2.70-2.90(2H,m),3.12(3H,m),3.38(2H,m),3.74(2H,m),4.49(1H,m),5.55(1H,bs),7.10-7.30(4H,m),7.35-7.55(3H,m),7.69(1H,s),7.75-7.95(5H,m),8.23(2H,m)	503
156	2		2.00(4H,m),2.30(2H,m),2.86(1H,m),3.07(1H,m),3.45-4.00(6H,m),4.49(1H,m),5.50(2H,m),7.10-7.30(4H,m),7.30-7.50(3H,m),7.67(1H,s),7.75-7.95(3H,m),8.04(2H,b),8.25(2H,m)	499
157	2		2.02(4H,m),2.29(2H,m),2.86(1H,dd),3.12(1H,dd),3.71(2H,s),3.60-4.10(2H,m),3.95(2H,d),4.52(1H,m),7.10-7.30(4H,m),7.35-7.50(3H,m),7.68(1H,s),7.70-7.90(3H,m),8.26(1H,d),8.34(2H,bs),8.54(1H,t)	497




Example number	o	D	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
158	2		2.25-3.60(13H,m),4.20(1H,m),4.35(1H,m),6.85-7.15(8H,m),7.35-7.50(3H,m),7.72(1H,s),7.80-8.00(5H,m),8.29(1H,t),8.38(1H,d)	535
159	2		1.66(2H,m),2.30-3.55(13H,m),4.24(1H,m),4.51(1H,m),6.85-7.15(8H,m),7.40-7.55(3H,m),7.71(1H,s),7.80-7.95(5H,m),8.22(1H,t),8.36(1H,d)	549
160	2		2.25-3.60(13H,m),3.73(1H,m),4.22(1H,m),4.57(1H,m),5.55(1H,bs),6.85-7.15(8H,m),7.47(3H,m),7.73(1H,s),7.80-7.95(m,5H),8.27(1H,t),8.34(1H,m)	565
161	2		2.42(2H,m),2.70(2H,m),2.85-3.20(4H,m),3.50(3H,m),3.75(2H,m),4.15-4.65(2H,m),5.51(2H,m),6.85-7.15(8H,m),7.46(3H,m),7.71(1H,s),7.75-7.90(3H,m),8.08(2H,bs),8.35(2H,m)	561
162	2		2.41(2H,m),2.69(2H,m),2.85-3.25(4H,m),3.34(2H,m),4.22(1H,m),4.59(1H,m),5.55(1H,m),5.70(1H,m),6.85-7.15(8H,m),7.48(3H,m),7.73(1H,s),7.83(3H,m),8.02(2H,bs),8.34(2H,m)	561
163	2		2.40(2H,m),2.67(2H,m),2.80-3.20(4H,m),3.50(1H,m),3.71(2H,m),3.99(2H,m),4.21(1H,m),4.58(1H,m),6.85-7.15(8H,m),7.48(3H,m),7.72(1H,s),7.82(3H,m),8.35(3H,m),8.60(1H,t)	559




Example number	M1	D1	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
164			0.50-1.05(3H,m),2.35(2H,m),2.84(3H,m),3.10-3.60(8H,m),3.60-4.65(1H,m),7.23(1H,m),7.45(6H,m),7.68(1H,s),7.75-8.10(5H,m),8.10-8.45(2H,m)	505
165			0.45-1.15(3H,m),1.15-1.80(2H,m),2.15-2.45(2H,m),2.50-3.00(4H,m),3.00-3.75(7H,m),3.85-4.65(1H,m),7.10-8.35(15H,m)	519
166			1.10(6H,s),1.30-1.65(2H,m),1.95-2.20(2H,m),2.20-2.45(2H,m),2.95(1H,dd),3.99(1H,bs),4.57(1H,m),7.25(1H,t),7.30-7.55(4H,m),7.59(1H,d),7.65,8.05(7H,m),8.22(1H,d),8.33(1H,t)	533
167			1.26(2H,m),1.95-2.72(6H,m),2.73-3.10(3H,m),3.11-3.75(6H,m),4.10(2H,m),4.50(1H,m),4.89(1H,m),7.20-7.40(2H,m),7.45(4H,m),7.60(2H,m),7.75(3H,m),8.22(1H,t),8.37(1H,d)	545
168			2.25-2.75(8H,m),3.05-3.40(6H,m),3.51(2H,m),4.30-4.70(2H,m),6.96(1H,m),7.10-7.50(7H,m),7.50-7.85(5H,m)	535
169			1.30-1.60(2H,m),1.60-1.80(2H,m),1.95-2.15(2H,m),2.15-2.45(2H,m),2.70-2.95(4H,m),3.55-3.70(2H,m),3.97(1H,bs),3.47(1H,m),5.27(1H,bs),7.24(1H,t),7.30-7.50(5H,m),7.58(1H,d),7.65-7.90(4H,m),8.10-8.25(2H,m),8.61(1H,bs)	563
170			1.15(6H,s),1.35-1.60(2H,m),1.65-1.85(2H,m),2.00-2.15(2H,m),2.20-2.45(2H,m),2.65-2.85(2H,m),2.92(1H,dd),3.05-3.45(7H,m),3.95(1H,bs),4.48(1H,m),5.58(1H,s),7.24(1H,t),7.35-7.50(4H,m),7.58(1H,d),7.65-7.90(4H,m),8.10-8.45(4H,m)	591
171			1.16(3H,d),1.22(3H,s),1.30-1.60(2H,m),1.95-2.15(2H,m),2.20-2.45(2H,m),2.80-3.60(8H,m),3.94(1H,bs),4.50-4.70(1H,m),7.24(1H,t),7.30-7.50(5H,m),7.58(1H,d),7.65-7.95(6H,m),8.05-8.30(2H,m)	563
172			1.80(3H,d),1.30-1.60(2H,m),1.95-2.15(2H,m),2.20-2.45(2H,m),2.60-2.80(2H,m),2.80-3.65(9H,m),3.75-4.10(3H,m),4.45-4.60(1H,m),5.30(1H,bs),5.60(1H,bs),7.24(1H,bs),7.30-7.50(5H,m),7.58(1H,d),7.65-7.90(5H,m),8.10-8.35(2H,m)	593



















Example number	M ¹	D ¹	¹ H-NMR (δ ppm) :	FAB-MS (M+H) ⁺
173			2.00–2.55(4H,m), 2.65–4.30(16H,m), 7.26(1H,m), 7.45(5H,m), 7.70(1H,s), 7.75–7.90(3H,m), 8.52(1H,d)	547
174			1.22–1.65(2H,m), 1.65–1.85(2H,m), 1.95–2.15(2H,m), 2.20–2.45(2H,m), 3.95(1H,bs), 4.98(1H,bs), 7.24(1H,t), 7.30–7.50(4H,m), 7.58(1H,d), 7.65–8.05(5H,m), 8.32(1H,t)	563
175			1.30–1.65(2H,m), 1.65–1.80(2H,m), 1.90(3H,s), 1.95–2.15(2H,m), 2.20–2.50(2H,m), 2.60–2.85(2H,m), 2.85–3.75(10H,m), 3.90–4.15(2H,m), 4.85–5.05(1H,m), 7.24(1H,t), 7.30–7.55(4H,m), 7.58(1H,d), 7.65–8.05(5H,m), 8.25–8.45(1H,m)	605
176			1.40–1.60(2H,m), 1.75–1.90(2H,m), 2.00–2.15(2H,m), 2.30–2.45(2H,m), 2.95(2H,bs), 3.15(4H,bs), 3.90–4.00(1H,m), 4.40–4.50(1H,m), 7.1(1H,bs), 7.25(1H,bs), 7.35–7.50(4H,m), 7.55–7.90(7H,m), 8.15(1H,s), 8.20–8.30(5H,m)	—
177			1.35–1.95(4H,m), 2.00–2.55(4H,m), 2.64(1H,m), 2.90–3.55(8H,m), 3.85–4.60(1H,m), 4.73(1H,m), 6.92(1H,m), 7.00–7.50(6H,m), 7.52(1H,d), 7.69(4H,m), 8.18(1H,m)	561
178			1.30–1.60(2H,m), 1.65–1.85(2H,m), 2.00–2.15(2H,m), 2.20–2.45(2H,m), 2.70–3.00(3H,m), 3.20–3.70(8H,m), 3.85–4.10(1H,m), 4.40–4.55(1H,m), 7.24(1H,t), 7.35–7.65(6H,m), 7.65–7.95(9H,m), 8.10–8.30(2H,m), 8.88(2H,bs)	576
179			0.45–1.10(3H,m), 1.46(6H,m), 2.35(2H,m), 2.89(1H,m), 3.05–3.75(10H,m), 3.80–4.65(1H,m), 7.15–7.62(7H,m), 7.69(1H,s), 7.76(3H,m), 8.22(5H,m)	590
180			1.70–1.95(2H,m), 2.30–2.65(4H,m), 3.03(2H,m), 3.15–3.40(4H,m), 3.64(2H,m), 3.74(2H,t), 4.40–4.75(2H,m), 6.81(1H,s), 6.97(1H,s), 7.20–7.55(7H,m), 7.56–7.90(5H,m)	556
181			1.35–1.60(2H,m), 2.00–2.10(2H,m), 2.25–2.45(3H,m), 2.55–2.70(1H,m), 2.75–3.00(3H,m), 3.00–3.40(4H,m), 3.70–3.80(1H,m), 3.90–4.00(1H,m), 4.45–4.55(1H,m), 7.25(2H,t), 7.35–7.50(5H,m), 7.55(1H,d), 7.70(1H,s), 7.65–7.90(6H,m), 8.15(1H,d), 8.20–8.35(1H,m)	535
182			1.35–1.60(2H,m), 2.0–2.10(2H,m), 2.25–2.45(2H,m), 2.55–2.70(1H,m), 2.80–2.95(2H,m), 3.0–3.4(6H,m), 3.70–3.80(1H,m), 3.90–4.00(1H,m), 4.45–4.55(1H,m), 7.25(1H,bs), 7.40–7.50(4H,m), 7.60(1H,d), 7.85–8.00(6H,m), 8.05–8.10(1H,m), 8.15(1H,d), 8.25(1H,bs)	535




Example number	M1	D1	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
183			1.25–1.55(2H,m), 1.60–1.80(2H,m), 2.05–2.45(4H,m), 2.65–3.50(12H,m), 3.90–4.10(1H,m), 5.05–5.35(1H,m), 7.15–8.15(14H,m)	533
184			2.05–2.45(3H,m), 2.50–2.95(6H,m), 2.95–3.55(7H,m), 3.65–3.90(1H,m), 3.95–4.20(1H,m), 5.15(1H,m), 5.55(1H,bs), 7.15–8.15(14H,m)	535
185			1.25–1.55(2H,m), 1.95–2.45(4H,m), 2.50–2.65(1H,m), 2.78(3H,s), 2.75–2.90(1H,m), 2.95–3.50(7H,m), 3.65–3.85(1H,m), 3.85–4.05(1H,m), 5.05–5.40(1H,m), 5.56(1H,bs), 7.10–8.10(14H,m)	549
















Example number	o	B1	D1	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
186	3			1.30–1.65(2H,m), 1.95–2.20(2H,m), 2.25–2.65(3H,m), 2.70–2.95(2H,m), 3.00–3.45(5H,m), 3.50–3.85(2H,m), 3.90–4.15(1H,m), 4.42(1H,m), 5.50(1H,bs), 6.85–7.15(3H,m), 7.15–7.65(6H,m), 7.83(2H,s), 8.01(1H,d), 8.16(1H,t), 10.81(1H,s)	524
187	2			1.55–1.75(2H,m), 2.05–2.45(3H,m), 2.60–2.90(3H,m), 3.00–3.65(7H,m), 3.90–4.30(1H,m), 4.35–4.55(1H,m), 7.20–7.75(13H,m), 7.86(2H,s), 8.20(1H,t), 8.30(1H,d)	559
188	3			1.35–1.75(4H,m), 2.00–2.15(2H,m), 2.25–2.45(2H,m), 2.65–2.95(3H,m), 3.00–3.45(6H,m), 4.22(1H,bs), 4.46(1H,m), 7.22(1H,t), 7.30–7.75(12H,m), 7.86(2H,s), 8.10–8.30(2H,m)	573
189	2			2.00–2.70(4H,m), 2.75–2.95(2H,m), 3.00–3.65(7H,m), 3.65–3.85(1H,m), 3.95–4.30(1H,m), 4.35–4.60(1H,m), 5.55(1H,bs), 7.20–7.75(13H,m), 7.85(2H,s), 8.15–8.40(2H,m)	575


Example number	o	B ¹	D ¹	¹ H-NMR (δ ppm) :	FAB-MS (M+H) ⁺
190	3			1.35-1.60(2H,m), 2.00-2.20(2H,m), 2.25-2.45(2H,m), 2.55-2.70(1H,m), 2.75-2.95(2H,m), 3.00-3.65(6H,m), 3.65-3.85(1H,m), 3.90-4.15(1H,m), 4.40-4.60(1H,m), 5.55(1H,bs), 7.22(1H,t), 7.30-7.75(12H,m), 7.89(2H,s), 8.17(1H,d), 8.28(1H,t)	589
191	3			1.50-1.75(4H,m), 2.10-2.25(2H,m), 2.30-2.45(2H,m), 2.75(2H,q), 3.14(2H,q), 3.20-3.50(3H,m), 3.56(2H,d), 4.11(1H,bs), 4.41(1H,q), 4.47(2H,s), 7.22-7.35(6H,m), 7.45-7.55(2H,m), 7.61(1H,d), 7.08(2H,s), 2.05(1H,d), 8.18(1H,t)	499
192	3			1.50-1.75(2H,m), 2.10-2.25(2H,m), 2.30-2.45(2H,m), 2.50-2.70(1H,m), 2.75-2.90(1H,m), 3.00-3.65(7H,m), 3.75(1H,bs), 4.12(1H,bs), 4.35-4.50(3H,m), 7.15-7.35(6H,m), 7.40-4.55(2H,m), 7.61(1H,d), 7.86(2H,s), 8.07(1H,d), 8.19(1H,t)	515
193	2			1.65(2H,m), 2.00-2.50(3H,m), 2.55-2.75(3H,m), 2.85(1H,dd), 3.09(2H,q), 3.15-3.60(3H,m), 4.02(1H,bs), 4.28(1H,bs), 5.03(2H,s), 6.87(2H,d), 7.10(2H,bd), 7.25-7.55(8H,m), 7.60(1H,d), 7.85(2H,bs), 8.12(1H,t), 8.19(1H,d)	561
194	3			1.52(2H,bs), 1.66(2H,m), 2.07(2H,bs), 2.60-2.80(3H,m), 2.89(1H,dd), 3.11(2H,q), 3.15-3.45(3H,m), 4.02(1H,bs), 4.31(1H,m), 5.03(2H,s), 6.87(2H,d), 7.12(2H,d), 7.20-7.55(8H,m), 7.60(1H,d), 7.85(2H,bs), 8.05(1H,d), 8.14(1H,t)	575
195	2			2.00-2.70(5H,m), 2.75-3.00(2H,m), 3.00-3.60(5H,m), 3.71(1H,bs), 4.10(1H,m), 4.32(1H,bs), 5.03(2H,s), 6.78(2H,d), 7.13(2H,d), 7.20-7.55(8H,m), 7.60(1H,d), 7.24(2H,bs), 8.05-8.25(2H,m)	577
196	3			1.51(2H,bs), 2.06(2H,bs), 2.39(2H,bs), 2.55-2.75(2H,m), 2.55-3.00(2H,m), 3.00-3.80(5H,m), 4.02(1H,bs), 4.35(1H,m), 5.03(2H,s), 6.87(2H,d), 7.13(2H,d), 7.20-7.55(8H,m), 7.60(1H,d), 7.86(2H,bs), 8.04(1H,d), 8.18(1H,t)	591
197	3			1.35-1.75(4H,m), 2.00-2.15(2H,m), 2.20-2.45(2H,m), 2.65-2.85(3H,m), 3.02(1H,dd), 3.05-3.55(5H,m), 4.00(1H,bs), 4.41(1H,m), 7.15-7.65(13H,m), 7.86(2H,s), 8.14(1H,d), 8.20(1H,t)	545
198	3			1.30-1.65(2H,m), 1.95-2.15(2H,m), 2.20-2.45(2H,m), 2.55-2.70(1H,m), 2.70-2.90(2H,m), 2.95-3.45(4H,m), 3.50-3.85(3H,m), 3.90-4.15(1H,m), 4.46(1H,m), 7.15-7.65(13H,m), 7.87(2H,s), 8.13(1H,d), 8.25(1H,t)	561










Example number	o	q	A ¹	¹ H-NMR (δ ppm) :	FAB-MS (M+H) ⁺
199	2	2		2.78(2H,m), 2.92(2H,m), 3.16(2H,m), 3.41(2H,m), 3.72(2H,q), 3.83(1H,m), 4.49-4.57(2H,m), 7.07-8.33(19H,m)	521
200	2	3		1.65(4H,bs), 2.70(2H,m), 2.88(1H,m), 3.10(2H,d), 3.70(2H,ABq), 3.82(2H,m), 4.47(1H,m), 4.58(1H,dd), 7.03-8.32(19H,m)	535
201	3	2		1.61(2H,m), 2.11(2H,m), 2.82(2H,m), 2.95(1H,m), 3.25(2H,m), 3.36(2H,m), 3.31(2H,ABq), 4.34(1H,m), 4.54(1H,m), 7.09-8.31(19H,m)	535
202	3	3		1.68(4H,d), 2.10(2H,m), 2.75(2H,m), 2.91(1H,m), 3.15(4H,m), 3.81(2H,ABq), 4.33(1H,m), 4.52(1H,m), 7.10-8.31(19H,m)	549
203	4	2		1.37(4H,bs), 2.05(2H,d), 2.85(2H,bs), 2.95(1H,m), 3.20(1H,m), 3.29(2H,m), 3.54(1H,m), 3.81(2H,ABq), 4.45(1H,m), 4.54(1H,m), 7.05-8.30(19H,m)	549
204	4	3		1.37(4H,bs), 1.66(2H,m), 2.05(2H,d), 2.71(2H,m), 2.92(1H,m), 3.12(2H,m), 3.54(1H,m), 3.81(2H,ABq), 4.43(1H,m), 4.52(2H,m), 7.07-8.31(19H,m)	563
205	2	2		2.80(2H,bs), 2.93(1H,m), 3.33(4H,m), 4.18(2H,m), 4.49(1H,m), 7.27-8.34(19H,m)	535
206	2	3		1.66(2H,m), 2.59-3.15(8H,m), 4.18(2H,m), 4.47(1H,m), 7.26-8.33(19H,m)	549
207	3	2		1.68(2H,t), 2.07(2H,t), 2.80(2H,m), 2.92(2H,m), 3.22(2H,m), 3.63-3.97(2H,m), 4.55(1H,m), 7.29-8.38(19H,m)	549
208	3	3		1.70(4H,q), 2.09(2H,t), 2.74(1H,m), 2.92(1H,m), 3.16(4H,m), 3.61-3.94(2H,m), 4.55(1H,m), 7.28-8.27(19H,m)	563
209	2	2		0.85-1.15(2H,m), 2.10-2.62(4H,m), 2.76-3.80(8H,m), 4.29-4.38(1H,m), 4.42-4.55(1H,m), 6.69(1H,d), 6.77(1H,d), 6.86-7.07(3H,m), 7.12-7.38(4H,m), 7.40-7.52(3H,m), 7.72-7.89(5H,m), 8.28-8.32(2H,m)	533


Example number	α	q	A ¹	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
210	2	3		1.63-1.69(4H,m), 2.25-2.38(1H,m), 2.67-2.70(2H,m), 2.76-2.89(1H,m), 3.10-3.29(4H,m), 3.25-3.40(3H,m), 4.20-4.50(2H,m), 6.71(1H,d), 6.78(1H,d), 6.82-7.07(4H,m)	547
211	3	2		1.01-1.14(2H,m), 2.06-2.64(2H,m), 2.74-3.02(3H,m), 3.15-3.97(7H,m), 4.23-4.37(1H,m), 4.40-4.52(1H,m), 6.73(1H,d), 6.82(1H,d), 6.86-7.09(3H,m), 7.12-7.30(2H,m), 7.37-7.57(3H,m), 7.69-7.99(5H,m), 8.26-8.34(2H,m)	547
212	3	3		1.30-1.50(4H,m), 1.64-1.72(2H,m), 2.02-2.06(2H,m), 2.74-2.80(2H,m), 2.89-3.00(2H,m), 3.14-3.42(7H,m), 4.10-4.50(2H,m), 6.72-7.23(4H,m), 7.40-7.60(3H,m), 7.70-8.00(6H,m), 8.15-8.27(2H,m)	561
213	4	2		1.35-1.50(2H,m), 2.05-2.10(2H,m), 2.81-2.98(4H,m), 3.10-3.38(7H,m), 4.47-4.60(2H,m), 6.70(1H,d), 6.82(1H,d), 6.88-7.25(5H,m), 7.40-7.50(3H,m), 7.73(1H,bs), 7.80-7.98(5H,m), 8.20-8.34(2H,m)	561
214	4	3		1.10-1.20(2H,m), 1.25-1.40(4H,m), 1.64-1.76(4H,m), 1.97-2.00(1H,m), 2.70-2.78(2H,m), 2.91-4.03(8H,m), 4.48-4.60(2H,m), 6.85-6.99(1H,m), 7.03-7.34(5H,m), 7.41-7.48(3H,m), 7.63-7.84(6H,m), 8.13-8.32(2H,m)	575
215	2	2		2.22-2.98(4H,m), 3.12(4H,m), 3.68(1H,m), 4.49(1H,m), 7.30-7.65(8H,m), 7.65-7.90(3H,m), 8.17(2H,bs), 8.35(2H,m)	539
216	2	3		1.66(2H,m), 2.20-2.78(4H,m), 2.88(1H,m), 3.10(1H,m), 3.68(1H,m), 3.91(1H,m), 4.96(1H,m), 7.18(1H,m), 7.30-8.00(12H,m), 8.19(1H,m), 8.32(1H,t)	553
217	3	2		1.50(2H,m), 2.06(2H,m), 2.70-3.00(3H,m), 3.15-3.45(3H,m), 3.47(1H,m), 4.33(1H,m), 4.44(1H,m), 7.10-7.86(1H,m), 7.91(2H,bs), 8.13(1H,d), 8.21(1H,m)	553
218	3	3		1.32-1.54(4H,m), 2.11(2H,m), 2.49-2.61(2H,m), 2.64-2.82(2H,m), 3.10(2H,m), 3.04-3.44(1H,m), 4.14-4.39(2H,m), 6.94-7.82(11H,m), 7.89(2H,bs), 8.18(2H,m)	567
219	4	2		1.17-1.45(4H,m), 2.01(2H,m), 2.70-2.97(3H,m), 3.13-3.52(4H,m), 4.36-4.58(2H,m), 7.17(1H,m), 7.34-7.52(5H,m), 7.54-7.63(2H,m), 7.69(1H,bs), 7.45-7.87(2H,m), 7.95(2H,bs), 8.14(1H,t), 8.26(1H,t)	567
220	4	3		1.15-1.65(4H,m), 1.65(2H,t), 2.01(2H,m), 2.66-2.78(2H,m), 2.89(1H,m), 3.06-3.18(2H,m), 4.34-4.65(2H,m), 7.20(1H,m), 7.33-7.49(2H,m), 7.53-7.66(2H,m), 7.69(1H,d), 7.75-7.89(4H,m), 8.12(1H,t), 8.18(1H,t)	581
221	2	2		2.77(2H,m), 2.91(1H,dd), 3.10-3.40(4H,m), 3.16(1H,dd), 4.51(1H,m), 4.66-4.95(2H,m), 7.34-7.87(11H,m), 7.95(2H,bs), 8.27(1H,m), 8.37(1H,dd)	555
222	2	3		1.64(2H,m), 2.89(1H,dd), 2.40-3.65(7H,m), 3.78(1H,m), 4.46-4.64(2H,m), 7.35-8.05(13H,m), 8.19(1H,m), 8.36(1H,d)	569

Example number	o	q	A ¹	¹ H-NMR(δ ppm) :	FAB- MS (M+H) ⁺
223	3	2		1.54-1.73(2H,m),2.14(2H,m),2.72-3.00(3H,m),3.13-3.62(4H,m),4.37(1H,m),4.53(1H,m),7.26-7.85(11H,m),8.04(2H,m),8.30(2H,m)	569
224	3	3		1.50-1.75(4H,m),2.14(2H,t),2.66-2.86(2H,m),2.89(1H,m),3.06-3.20(2H,m),3.20-3.60(2H,m),4.37(1H,m),4.51(1H,m),7.35-7.95(13H,m),8.17-8.27(2H,m)	583
225	4	2		1.20-1.45(4H,m),2.05(2H,m),2.80(2H,m),2.91(1H,m),3.10-3.52(4H,m),4.38-4.60(2H,m),7.35-7.85(11H,m),7.96(2H,m),8.17(1H,dd),8.27(1H,t)	583
226	4	3		1.20-1.46(4H,m),1.65(2H,m),2.04(2H,m),2.64-2.78(2H,m),2.90(1H,m),3.10(1H,m),3.15-3.55(2H,m),4.33-4.65(2H,m),7.36-7.88(13H,m),8.17(1H,m)	597
227	2	2		2.22-3.68(8H,m),3.85(1H,m),4.35-4.68(2H,m),7.33-7.55(4H,m),7.62-8.53(11H,m)	571
228	2	3		1.68(2H,m),2.24-3.68(8H,m),3.85(1H,m),4.35-4.72(2H,m),7.36-7.64(4H,m),7.64-8.47(11H,m)	585
229	3	2		1.45-1.85(2H,m),2.13(2H,m),2.43-3.64(4H,m),2.93(1H,dd),3.22(1H,dd),3.78(1H,m),4.31(1H,m),4.53(1H,m),7.22-8.18(13H,m),8.18-8.37(2H,m)	585
230	3	3		1.67(4H,m),2.12(2H,m),2.42-3.62(6H,m),3.73(1H,m),4.33(1H,m),4.51(1H,m),7.23-8.02(13H,m),8.22(2H,m)	599
231	4	2		1.27-1.55(4H,m),2.04(2H,m),2.80(2H,m),2.93(1H,dd),3.23-3.45(2H,m),3.29(1H,dd),3.67(1H,m),4.36(1H,m),4.52(1H,m),7.36-7.52(4H,m),7.68-8.04(9H,m),8.17(1H,t),8.26(1H,t)	599
232	4	3		1.28-1.58(4H,m),1.65(2H,m),2.04(2H,m),2.66-2.78(2H,m),2.91(1H,m),3.10(2H,m),3.20-3.50(1H,m),3.67(1H,m),4.37(1H,m),4.51(1H,m),7.36-7.53(4H,m),7.67-7.97(9H,m),8.12-8.20(2H,m)	613
233	2	3		1.28(6H,d),1.60-1.68(2H,m),2.62-2.93(5H,m),3.07-3.17(4H,m),4.14(2H,t),4.40-4.50(1H,m),7.33-7.47(4H,m),7.61-7.85(9H,m),8.20(1H,t),8.44(1H,d)	538
234	3	3		1.71(4H,m),2.19(2H,m),2.34(3H,s),2.45(3H,s),2.74(2H,m),2.91(1H,m),3.16(3H,m),3.48(1H,bs),3.96(1H,bs),4.66(1H,m),7.32(4H,m),7.45(1H,d),7.56(2H,m),7.68(3H,m),7.90(3H,m),8.36(2H,m)	541
235	2	3		1.07,1.11(3H,d),1.66(2H,m),1.80-2.15(1H,m),2.20-2.80(5H,m),2.89,3.01(3H,s),3.15(3H,m),3.65-3.95(2H,m),4.45-4.80(2H,m),7.25-7.55(6H,m),7.65-7.95(7H,m),8.15-8.50(2H,m)	580















Example number	o	A ¹	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
236	2		2.47(2H,m),2.86(2H,m),3.09(4H,m),3.79-4.05(4H,m), 4.55(2H,m),7.03-8.31(20H,m)	551
237	3		1.64(2H,m),2.09(2H,m),2.63(1H,m),2.89(2H,m),3.15 (4H,m),3.75(1H,m),3.80(2H,ABq),4.30(1H,m),4.56(1H, m),7.08-8.31(20H,m)	565
238	4		1.40(9H,s),1.62(4H,bs),1.75(2H,bs),2.22(2H,bs),2.90 (1H,m),3.22(4H,bs),4.09(1H,m),4.52(1H,m),4.75(1H, m),5.01(1H,m),6.45(1H,m),6.81(1H,bs),7.08-7.77(15H, m)	579
239	2		1.05-1.18(4H,m),1.22-1.39(2H,m),1.95-2.05(2H,m), 2.80-3.38(11H,m),4.50-4.60(2H,m),6.85-7.27(5H, m),7.50-7.34(4H,m),7.68-7.90(4H,m),7.90-8.00(2H, m),8.15-8.31(2H,m)	563
240	3		1.01-1.14(2H,m),2.10-2.03(2H,m),2.54-2.72(1H,m), 2.72-3.00(3H,m),3.02-4.25(10H,m),4.62-4.50(1H,m), 6.65-7.30(8H,m),7.35-7.58(3H,m),7.70-7.96(4H,m), 8.10-8.47(2H,m)	577
241	4		1.12-1.18(2H,m),1.23-1.49(2H,m),1.76(1H,d),2.14- 1.99(2H,m),2.79-2.49(1H,m),2.86-3.65(9H,m),3.80- 3.65(1H,m),4.09-4.55(1H,m),4.50-4.60(1H,m),5.53 (1H,bs),6.81-7.36(8H,m),7.39-7.78(3H,m),7.80-7.99 (4H,m),8.09-8.30(2H,m)	591
242	2		2.61(2H,m),2.85-2.94(2H,m),3.11(4H,m),3.72(1H,m), 4.15(2H,m),4.51(1H,m),7.27-8.32(20H,m)	565
243	3		1.67(2H,m),1.84(2H,m),2.03-2.32(3H,m),2.86(2H,m), 3.18(2H,m),4.15(1H,t),4.58(1H,m),7.29-8.31(20H,m)	579
244	2		2.55-3.60(8H,m),3.71(2H,m),4.55(2H,m),5.52(1H,m), 7.35-8.00(13H,m),8.24(1H,m),8.35(1H,m)	569
245	3		1.55(2H,m),2.11(2H,m),2.44(1H,m),2.54-3.44(6H,m), 4.35(1H,m),4.53(1H,m),5.55(1H,m),7.10-7.97(13H,m), 8.05-8.30(2H,m)	583


Example number	o	A ¹	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
246	3		1.13- 1.60(4H,m),1.99(2H,m),2.45- 3.80(8H,m),4.42 (1H,m),4.56(1H,m),7.19(1H,m),7.33- 7.53(5H,m),7.53 - 7.66(2H,m),7.70(1H,m),7.74- 7.95(4H,m)	597
247	2		2.22- 3.45(7H,m),3.74(2H,m),4.51(2H,m),5.59(1H,d), 7.32- 7.65(7H,m),7.39(1H,m),7.74(1H,m),7.78(1H,m), 7.85(1H,m),7.90- 8.03(2H,m),8.24- 8.39(2H,m)	585
248	3		1.62(2H,m),2.13(2H,t),2.40- 3.62(7H,m),3.74(1H,m), 4.36(1H,m),4.56(1H,m),5.56(1H,d),7.37- 7.90(13H,m), 8.25(2H,d)	599
249	4		1.15- 1.45(4H,m),2.03(2H,m),2.40- 2.68(1H,m),2.68 - 2.95(2H,m),3.00- 3.20(2H,m),3.20- 3.60(2H,m), 3.72(1H,m),4.44(1H,m),4.55(1H,m),5.55(1H,bs),7.36- 7.87(13H,m),8.14(1H,m),8.22(1H,m)	613
250	2		2.20- 2.70(3H,m),2.70- 2.95(2H,m),3.05- 3.25(2H,m), 3.27- 3.47(1H,m),3.65- 3.95(2H,m),4.33- 4.70(2H,m), 5.55(1H,m),7.37- 7.53(4H,m),7.60- 8.46(1H,m)	601
251	3		1.45- 1.85(2H,m),2.10(2H,m),2.45- 3.60(7H,m),2.78 (1H,dd),4.16- 4.61(2H,m),5.58(1H,d),7.20- 8.34(15H, m)	615
252	4		1.25- 1.57(4H,m),2.02(2H,m),2.40- 3.79(6H,m),4.28 - 4.60(4H,m),5.55(1H,d),7.37- 7.57(4H,m),7.63- 8.00 (9H,m),8.13(1H,t),8.22(1H,t)	629



Example number	A ¹	M ¹	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
253			0.45-1.15(3H,m), 2.15-2.45(2H,m), 2.50-2.70(1H,m), 2.75-3.00(2H,m), 3.20-3.55(8H,m), 3.60-3.85(1H,m), 4.05-4.65(1H,m), 5.56(1H,bs), 7.10-8.35(15H,m)	535
254			0.68(1H,d), 0.85-1.05(2H,m), 2.00-3.30(10H,m), 3.60-4.70(5H,m), 7.20-8.00(13H,m), 8.15-8.40(2H,m)	535
255			1.23(3H,m), 1.44(3H,m), 2.14(4H,m), 2.56(1H,m), 2.85(2H,m), 3.12(3H,m), 3.72(1H,m), 3.95-4.25(1H,m), 4.49(1H,m), 5.53(1H,d), 7.26(1H,m), 7.35-7.60(6H,m), 7.65-7.95(6H,m), 8.19(1H,d), 8.27(1H,t)	549
256			1.23(3H,m), 1.45(5H,m), 2.04(2H,m), 2.17(2H,m), 2.61(1H,bs), 2.90(1H,m), 3.15(3H,m), 3.74(1H,m), 3.95(1H,m), 4.53(1H,m), 5.55(1H,bs), 7.25(1H,m), 7.35-7.65(6H,m), 7.70-7.95(6H,m), 8.13(1H,t), 8.23(1H,d)	563
257			1.03(3H,s), 1.10(3H,s), 2.60(2H,t), 2.90(3H,m), 3.19(3H,m), 3.59(2H,t), 3.76(1H,m), 4.62(1H,m), 7.06(1H,t), 7.23(1H,t), 7.35(1H,d), 7.45(3H,m), 7.65-7.95(8H,m), 8.22(1H,t)	581
258			1.16(1H,m), 1.50(1H,m), 1.64-1.89(2H,m), 1.90-2.23(3H,m), 2.28-2.96(6H,m), 3.00-3.28(3H,m), 3.72(1H,m), 4.13(1H,m), 4.49(1H,m), 5.56(1H,bs)	535
259			1.90(4H,m), 2.25(2H,t), 2.42(1H,m), 2.70-2.95(2H,m), 3.00-3.20(3H,m), 3.40(1H,m), 3.56(1H,m), 3.70(2H,m), 4.05-4.25(2H,m), 4.46(1H,m), 5.53(1H,d), 7.35-7.52(4H,m), 7.61(1H,dd), 7.68(1H,d), 7.70-7.95(6H,m), 8.19(1H,t), 8.26(1H,m)	592
260			1.90(4H,m), 2.20-2.60(3H,m), 2.85(2H,m), 3.14(3H,m), 3.40(1H,m), 3.57(1H,m), 3.74(2H,m), 4.02(2H,m), 4.52(1H,m), 7.30-7.60(7H,m), 7.70-7.95(6H,m), 8.22(1H,t), 8.32(1H,d)	558
261			1.50(2H,m), 1.95(6H,m), 2.42(1H,m), 2.60(1H,m), 2.75-2.95(2H,m), 3.15(3H,m), 3.35-3.80(4H,m), 4.03(1H,m), 4.56(1H,m), 7.40(5H,m), 7.56(1H,m), 7.71(5H,m), 7.88(2H,bs), 8.18(1H,d), 8.27(1H,t)	572
262			0.35-0.80(3H,m), 1.92(4H,m), 2.20-3.90(11H,m), 4.07(1H,m), 4.14-4.62(2H,m), 7.20-7.62(6H,m), 7.63-8.00(7H,m), 8.01-8.38(2H,m)	572

Example number	A ¹	M ¹	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
263			0.40–0.90(6H,m), 1.91(4H,m), 2.40(1H,m), 2.62(1H,m), 2.87(1H,m), 2.95–3.85(7H,m), 4.04(1H,m), 7.25–7.50(6H,m), 7.69(2H,m), 7.75–8.00(6H,m), 8.16(1H,m)	586
264			1.25–2.00(6H,m), 2.27(2H,m), 2.50–2.95(3H,m), 3.12(3H,m), 3.72(3H,m), 4.11(1H,m), 4.28(1H,m), 4.48(1H,m), 7.25–7.60(6H,m), 7.60–7.73(2H,m), 7.74–7.95(5H,m), 8.18(1H,t), 8.32(1H,d)	572
265			2.20(3H,s), 2.58–3.45(8H,m), 3.72–3.88(1H,m), 4.25–4.50(2H,m), 4.60–4.72(1H,m), 5.64(1H,bs), 7.13–7.35(4H,m), 7.44–7.65(8H,m), 7.77–7.97(6H,m), 8.39(1H,t), 8.59(1H,d)	605
266			1.50–1.70(2H,m), 2.23(3H,s), 2.57–3.55(8H,m), 3.75–3.85(1H,m), 4.30–4.50(2H,m), 4.60–4.70(1H,m), 5.70(1H,bs), 7.15–7.37(4H,m), 7.44–7.66(8H,m), 7.77–7.98(6H,m), 8.35(1H,t), 8.60(1H,d)	619
267			1.28(3H,t), 2.58–3.26(6H,m), 3.88–4.03(1H,m), 4.21(2H,q), 4.61–4.74(1H,m), 5.12(2H,s), 7.38–7.58(5H,m), 7.70–7.88(4H,m), 7.90(2H,bs), 8.18(1H,d), 8.50(1H,bt), 8.62(1H,s), 9.00(1H,d)	579
268			1.28(6H,d), 2.63–2.73(1H,m), 2.74–2.94(2H,m), 3.12–3.19(4H,m), 3.33(2H,s), 3.74–3.82(1H,m), 4.13(2H,t), 4.53–4.56(1H,m), 5.56(1H,bs), 7.35–7.49(4H,m), 7.61–7.89(9H,m), 8.23(1H,t), 8.31–8.46(1H,m)	554

-73-




Example number	A ¹	M ¹	D ¹	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
269				2.01,2.04(3H,s),2.35-3.63(8H,m),4.05(2H,m),4.54(1H,m),4.95(1H,m),7.21(2H,m),7.31(3H,m),7.44(4H,m),7.56(1H,m),7.65-7.90(5H,m),8.08(2H,bs),8.36(2H,m)	595
270				2.55(2H,m),2.93(1H,m),3.20(1H,m),3.35(2H,m),4.06(4H,m),4.65(1H,m),7.20(2H,m),7.32(3H,m),7.45(5H,m),7.56(1H,m),7.68(1H,m),7.70-7.90(4H,m),8.20(2H,bs),8.44(1H,d),8.58(1H,t)	551
271				1.16(1H,m),1.50(1H,m),1.65-2.25(7H,m),2.30-3.30(4H,m),3.85-4.25(3H,m),4.47(1H,m),7.24(4H,m),7.46(3H,m),7.72(1H,s),7.75-7.95(3H,m),8.05-8.60(4H,m),10.08,10.30(1H,bs)	530

Example number	Structure	¹ H-NMR(δ ppm) :	FAB-MS (M+H) ⁺
272		1.64-1.70(4H,m),2.42-2.82(6H,m),3.11-3.18(8H,m),3.34-3.50(3H,m),4.08-4.14(4H,m),4.20-4.60(2H,m),6.29-7.40(11H,m),7.84(1H,bs),8.10-8.20(1H,m)	551
273		0.67(2H,d),0.85(2H,d),1.00-1.35(2H,m),1.35-1.65(3H,m),2.25-2.70(3H,m),2.70-3.55(10H,m),3.65-3.85(1H,m),4.50-4.80(1H,m),6.05(1H,bs),7.25-7.55(3H,m),7.65-8.05(6H,m),8.20-8.40(2H,m)	469

What is ~~claim~~ed is ;

1. A ~~compound~~ having a Formula I :



wherein

A is a lipophilic group comprising an aliphatic bridging group, and


B is a lipophilic group, and

D is a group having at least one amino or substituted amino group, and

R is hydrogen, alkyl, or cycloalkyl,

and pharmaceutically acceptable salts and individual isomers thereof.

2. A ~~compound~~, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 1 wherein A is :




wherein

A¹ is an aliphatic or aromatic ring which may have at least one hetero atom, and

M¹ is substituted or unsubstituted alkylene.

3. A ~~compound~~, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 2 wherein A¹ is :




wherein

A² is single or fused ring, each ring constituting A² is an aliphatic or aromatic ring which may have at least one hetero atom, each ring constituting A² may be substituted by at least one group selected from halogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, perfluoroalkyl, perfluoroalkoxy, cyano, nitro, substituted sulfonyl, substituted sulfinyl, substituted sulfinyl, mercapto, substituted carbonyl, amino, substituted amino, aryl, and substituted aryl, and

M¹ is alkylene which may be substituted by halogen, hydroxy, (C₁-C₅)alkyl, and / or (C₁-C₅)alkoxy.

4. A compound, and pharmaceutically acceptable salts and individual isomers thereof

according to Claim 3 wherein A¹ is :



wherein

A³ is a 5, 6, or 7 membered aromatic ring which may be comprised of at least one hetero atom, and may be substituted by a group selected from halogen, hydroxy, (C₁-C₅)alkyl, (C₁-C₅)alkoxy, (C₁-C₅)perfluoroalkyl, (C₁-C₅)perfluoroalkoxy, nitro, cyano, substituted sulfonyl, substituted sulfenyl, substituted sulfinyl, mercapto, amino, substituted amino, substituted carbonyl, phenyl and / or substituted phenyl, and

A³ can be fused with at least 5 to 8 membered aliphatic or aromatic ring which may be consisted of at least one hetero atom, and

l is 0, 1, or 2, and

X is -CH₂-, -O-, -S(O)r-, -C(O)-, -C(S)-, -CH=CH-, -CH(OH)-, or -NR⁴-, and


R⁴ is hydrogen, (C₁-C₅)alkyl, (C₃-C₈)cycloalkyl, acyl, or alkoxycarbonyl, and

m is 0, 1, or 2, and

Y is -C(O)-, -C(S)-, or (C₁-C₅)alkylene which may be substituted by (C₁-C₅)alkyl, p is 0, 1, or 2, and

r is 0, 1, or 2, and


Z is substituted or unsubstituted (C₁-C₅)alkylene, -NR⁴-, or



wherein

A⁴ is a 5 or 6 membered aromatic ring which may be comprised of at least one hetero atom, and

A⁴ may be substituted by a group selected from halogen, hydroxy, (C₁-C₅)alkyl, (C₁-C₅)alkoxy, (C₁-C₅)perfluoroalkyl, (C₁-C₅)perfluoroalkoxy, nitro, cyano, amino, substituted amino, phenyl and / or substituted phenyl, or



wherein

- 5 G_1 and G_2 are independently carbon or nitrogen, and
 one of --- may represent double bond when either G_1 and G_2 or G_2 and G_3 are carbon,
 and
 G_3 , G_4 , and G_5 are independently $-\text{O}-$, $-\text{S}(\text{O})\text{r}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{S})-$, $-\text{CH}=\text{CH}-$,
 $-\text{CH}(\text{OH})-$, $-\text{NR}^4-$, or $(\text{C}_1-\text{C}_5)\text{alkylene}$,
 10 r is 0, 1, or 2, and
 n is 0 or 1.

5. A compound, and pharmaceutically acceptable salts and individual isomers thereof
 according to Claim 4 wherein A^1 is selected from :

- 15 10,11-Dihydrodibenzo[b,f][1,4]oxazepin-11-one,
 3,4-Dihydro-2H-quinoline,
 2-Oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocine,
 2,3-Dioxo-2,3-dihydro-indole,
 2-Oxo-3,4-dihydro-2H-quinoline,
 3-Oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazine,
 20 4-Methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepine,
 2,3-Dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11(10H,11aH)-dione,
 3-Oxo-2,3-dihydro-benzo[l,4]thiazine,
 6-Oxo-11,12-dihydro-6H-dibenzo[b,f]azocine,
 2-Oxo-2,3,4,5-tetrahydrobenzo[b]azepine,
 25 1,1,4-Trioxo-2,3-dihydro-benzo[1,5]thiazepine,
 4-Oxo-2,3-dihydro-1,5-benzothiazepine,
 5,11-Dihydro-dibenzo[b,e]azepine,
 5H-Dibenzo[b,e]azepin-6,11-dione,
 5H-Dibenzo[b,f]azocin-6-one,
 10H-Dibenzo[b,f][1,4]thiazepin-11-one,
 30 5-Oxo-5,10H-dibenzo[b,f][1,4]thiazepin-11-one,
 5,5-Dioxo-5,10H-dibenzo[b,f][1,4]thiazepin-11-one,
 4-Oxo-2,3-dihydro-[1,5]benzoxazepine,
 6,12-Dioxo-6,6a,7,8,9,10-exahydro-12H-benzo[e]-pyrido[1,2-a][1,4]diazepine,
 2-Oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrole and
 Phenothiazine, each of which may be substituted.



35 6. A compound, and pharmaceutically acceptable salts and individual isomers thereof
 according to Claim 1 wherein :

B is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, or aryl, arylalkyl or
 arylalkoxyalkyl which may be substituted on their aromatic ring.

7. A compound, and pharmaceutically acceptable salts and individual isomers thereof
 according to Claim 6 wherein :

B is substituted or unsubstituted (C₆–C₂₀)alkyl, phenylalkyl, naphthylalkyl, 5,6,7,8-tetrahydro-naphthylalkyl, indolylalkyl, quinolylalkyl, or phenylalkoxyalkyl, which may be substituted by a group selected from halogen, hydroxy, (C₁–C₅)alkyl, (C₁–C₅)alkoxy, nitro, cyano, amino, substituted amino, phenyl, or substituted phenyl.

- 5 8. A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 1 wherein D is :





or

wherein

R¹ is hydrogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl, and R² and R³ are independently hydrogen, alkyl, substituted alkyl, acyl, amidino, alkoxy, carbonyl, or either R² or R³ can be taken together with R¹ to form alkylene, and

- 10 R² and R³ can be taken together to form alkylene, or heterocycle, and

M² is :



or



wherein

x, y and z are independently an integer of 0 to 4, and

- 15 R⁵, R⁶, R⁷ and R⁸ are independently hydrogen, halogen, alkyl, substituted alkyl, ---OR^9 , ---SR^9 , $\text{---NR}^9\text{R}^{10}$, ---NHC(O)R^9 , ---C(O)OR^9 , ---OCOR^9 , ---OC(O)OR^9 , $\text{---CONR}^9\text{R}^{10}$,

or can be taken together with R¹ or R² to form alkylene or heterocycle,

R⁹ and R¹⁰ are independently hydrogen, alkyl, substituted alkyl, and

R⁹ can be taken together with R¹ or R² to form alkylene,

R⁵ and R⁷ or R⁶ and R⁸ can be taken together to form alkylene or heterocycle, or

- 20 R⁵ and R⁶ or R⁷ and R⁸ can be taken together with the carbon atom to which R⁵ and R⁶, or R⁷ and R⁸ are bonded, respectively, to form carbonyl, thiocarbonyl or imino, and

E is oxygen atom or sulfur atom.

9. A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 8 wherein D is :

R^1 is hydrogen, (C_1-C_5) alkyl, (C_3-C_8) cycloalkyl, (C_1-C_5) hydroxyalkyl, or (C_1-C_5) aminoalkyl, and

5 R^2 and R^3 are independently hydrogen, (C_1-C_5) alkyl, substituted (C_1-C_5) alkyl, (C_1-C_6) acyl, or (C_1-C_6) alkoxycarbonyl, and

R^1 and R^2 or R^2 and R^3 can be taken together to form alkylene,














R^5 , R^6 , R^7 , and R^8 are independently hydrogen, halogen, (C_1-C_5) alkyl, substituted (C_1-C_6) alkyl, $-OR^9$, $-SR^9$, $-NR^9R^{10}$, $-OC(O)OR^9$, $-NHC(O)R^9$, $-C(O)OR^9$, and




















10 R^5 can be taken together with R^1 or R^2 to form alkylene,













R^9 and R^{10} are independently hydrogen, (C_1-C_5) alkyl, and

R^9 can be taken together with R^1 or R^2 to form alkylene.

10. A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 9 wherein D is selected from:







and

11. A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 2 wherein :

B is as defined in Claim 6 and D is as defined in Claim 8.

12. A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 2 wherein :

B is as defined in Claim 7 and D is as defined in Claim 10.

13. A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 4 wherein :

B is as defined in Claim 7 and D is as defined in Claim 8.

14. A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 5 wherein :

B is as defined in Claim 6 and D is as defined in Claim 10.

15. A compound of Claim 2 which is selected from :

- 5 N-(2-Aminomethyl)-3-phenyl-2(R)-[2-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetylaminolpropionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)propionamide;
- 3-(3-Acetyl-amino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-N-[1(R)-(2-amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]propionamide;
- N-[1(R)-(3-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-11,12-dibenzo[b,f]azocin-5-yl)propionamide;
- N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-11,12-dibenzo[b,f]azocin-5-yl)propionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;
- N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro- [1,5]benzothiazepin-5-yl)propionamide;
- 20 N-(4-Aminobutyl)-3-(naphthalen-2-yl)-2(R)-[2-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetylaminolpropionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H- dibenzo [b,f][1,4]oxazepin-10-yl)propionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H-(11a,5)-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)propionamide;
- 25 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro- [1,5]benzothiazepin-5-yl)butyramide;
- N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-methyl-2,5-dioxo-30 2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl)propionamide;
- N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro- benzo [3,2-b][1,4]oxazin-4-yl)propionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)propionamide;
- 35 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;
- N-(2-Amino-2-methylpropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-propionylamino]propionamide
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-40 dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-4-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-4-(3-oxo-2,3-dihydro-benzo[1,4]thiazin-4-yl)butyramide;

5 N-[1(R)-(3-Methylamino-propylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Methylamino-propylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

10 N-(1(R)-[(3-Aminopropyl)-methylcarbamoyle]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

15 N-[1(R)-(2-Amino-ethylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(1(R)-[Bis-(3-aminopropyl)carbamoyle]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

20 N-[1(R)-(3-Amino-propylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-4-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-4-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-3-phenothiazin-10-yl-propionamide

25 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;

30 N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

35 N-[1(R)-(2-aminoethylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

N-[1(R)-(3-Aminopropylcarbamoyle)-2-(1H-indol-3-yl)-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

40 N-[1(R)-(3-Aminopropylcarbamoyle)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyle)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,4-dioxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

5 N-[1(R)-(3-Amino-2-hydroxypropylcarbamyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)propionamide;

10 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H,(11aS)-pyrrolo[2,1-c][1,4]diazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(phenothiazin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)butyramide;

15 N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalene-2-yl)ethyl]-3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalene-2-yl)-2(R)-β-(4-oxo-7-trifluoromethyl-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide;

20 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-β-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

25 N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]-3-(naphthalen-2-yl)propionamide

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-[1,5]-benzothiazepin-5-yl)butyramide;

30 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]-azepin-5-yl)propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

35 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo-[b,e]-azepin-5-yl)propionamide;

40 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;


N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]thiazepin-10-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]-thiazepin-10-yl)propionamide;
- 5 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,11-dioxo-5,11-dihydrodibenzo-[b,f][1,4]thiazepin-10-yl)pentanamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,5,11-trioxo-5,11-dihydro-dibenzo[b,f][1,4]thiazepin-10-yl)pentanamide;
- 10 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-chloro-5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;
- 15 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,12-dioxo-6,6a,7,8,9,10-hexahydro-12H-benzo[e]pyrido[1,2-a][1,4]diazepine-5-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(9-fluoro-2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;
- N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]-thiazepin-5-yl)propionamide;
- 20 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;
- N-[1(R)-(3-amino-2(S)-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-
- 25 (5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;
- N-[1(R)-(3-amino-2(R)-hydroxy-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butanamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-
- 30 3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(1,1,4-trioxo-benzo-[1,5]thiazepin-5-yl)propionamide;
- N-[1(R)-(3-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-
- 35 dihydro-[1,5]benzothiazepin-5-yl)propionamide;
- N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-3,4-dihydro[1,5]benzothiazepin-5-yl)butyramide;
- N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-cyano-5-isopropyl-2-oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrol-1-yl)propionamide;
- 40 N-[1(R)-(3-Amino-2-hydroxycarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10-yl)propionamide; and
- N-[1(R)-[2-Hydroxy-3-(2(R)-hydroxypropylamino)propylcarbamoyl]-2-naphthalen-2-yl-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide.

16. A composition useful for increasing the level of growth hormone in a human or an animal which comprises an inert carrier and an effective amount of a compound according to any one of Claims 1 to 15.
- 5 17. A composition useful for increasing the level of growth hormone in a human or an animal which comprises an inert carrier, an effective amount of a compound according to any one of Claims 1 to 15 and a growth hormone secretagogues selected from KP-102(GHRP-2), GHRP-6, Hexarelin, GHRP-1, L-692,429, L-692,585, MK-0677, G-7220, or growth hormone releasing factor (GRF), IGF-1, IGF-2, or B-HT920 or said growth hormone.
- 10 18. A method for increasing levels of endogenous growth hormones in a human or an animal which comprises administering to such human or animal an effective amount of a compound according to any one of Claims 1 to 15.
- 15 19. A method for treating or preventing diseases or conditions which may be treated or prevented by growth hormone which comprises administering to a human or an animal of such treatment or prevention an amount of a compound according to any one of Claims 1 to 15 which is effective in promoting release of said growth hormone.
- 20 20. A method of Claim 19 wherein the disease or condition is selected from the group consisting of : osteoporosis; catabolic illness; immune deficiency, including that in individuals with a depressed T4/T8 cellratio; hip fracture; musculoskeletal impairment in the elderly; growth hormone deficiency in adults or in children; obesity; cachexia and protein loss due to chronic illness such as AIDS or cancer; and treatment of patients recovering from major surgery, wounds or burns.
- 25 21. A method for increasing the level of growth hormone in a human or an animals which comprises administering to a patient a compound according to any one of Claims 1 to 15 in combination with an additional growth hormone secretagogue selected from KP-102(GHRP-2), GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor(GRF), IGF-1, IGF-2, B-HT920 or said growth hormone.
- 30 22. A method for the treatment of osteoporosis which comprises administering to a patient with osteoporosis a combination of a bisphosphonate compound such as alendronate, and a compound according to any one of Claims 1 to 15.
23. A method for the treatment of bone fractures, wounds or burns which comprises administering to a patient with bone fractures, wounds or burns a combination of a growth factor such as FGF (fibroblast growth factor), PDBF (platelet-derived growth factor) and a compound according to any one of Claims 1 to 15.

24. A method to increase the rate and extent of growth of animals, to increase the milk or wool production of animals, or for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of Claims 1 to 15.


5. 25. A process for the preparation of a compound having a formula:



wherein A, R, B and D are as defined in Claim 1
which comprises reacting a compound having a formula :




wherein R^{11} is a leaving group and A is as defined in Claim 1
with a compound having a formula :




15 wherein R, B and D are as defined in Claim 1

26. A process for the preparation of a compound having a formula :




wherein R and B are as defined in Claim 1,
 A^1 and M^1 are as defined in Claim 2, and
 R^1 , R^2 , R^3 and M^2 are as defined in Claim 8

20 which comprises reacting a compound having a formula :



wherein A^1 and M^1 are as defined above and R^{11} is as defined in Claim 25,
with a compound having a formula



II


or




III

wherein L is a protecting group of amino acid and B, M^2 , R, R^1 , R^2 , and R^3 are as defined above, in an inert solvent.

- 5 27. A process for the preparation of a compound having a formula :



wherein A, B, D and R are as defined in Claim 1,
which comprises reacting a compound having a formula :




wherein R^{12} is a leaving group and A, B, and R are as defined above,
with a compound having a formula :




- 10 wherein D is as defined above, in an inert solvent.


28. A process for the preparation of a compound having a formula :



wherein B and R are as defined in Claim 1 and A^1 and M^1 are as defined in Claim 2
and R^1 , R^2 , R^3 , and M^2 are as defined in Claim 8,
which comprises reacting a compound having a formula :




wherein A^1 , M^1 , B, and R are as defined in above and R^{12} is as defined in Claim 27, with a compound having a formula :



IV


or



V

wherein R^1 , R^2 , R^3 , M^2 and L are as defined above, in an inert solvent, and comprises deprotecting L.


29. A compound having a formula :



wherein A^1 , M^1 are as defined in Claim 2, and R is as defined in Claim 1, and R^{12} is as defined in Claim 27.

30. A compound of Claim 29 wherein A^1 is as defined in Claim 4.

31. A compound having a formula :



10 wherein R and B are as defined in Claim 1 and R^1 , R^2 , R^3 , and M^2 are as defined in Claim 8.

32. A compound of Claim 31 wherein B is as defined in Claim 6 and R^1 , R^2 , R^3 , and R^5 , R^6 , R^7 , and R^8 in M^2 are as defined in Claim 9.

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL AMIDE DERIVATIVES

the specification of which (check applicable box(es)):

☐ is attached hereto

☐ was filed on _____

☒ was filed as PCT International application No. _____

as U.S. Application Serial No. _____

(Atty Dkt. No. 2554-7)

PCT/US98/17232

on **20 August 1998**

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number

Country

Day/Month/Year Filed

08/916,575

US

22 August 1997

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number

Date/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.

Day/Month/Year Filed

Status: patented

pending, abandoned

PCT/US98/17232

20 August 1998

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed)**, and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastoya, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoads, 37515. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

- Inventor's Signature: Hidenori FUNAMIZU Date: April 5, 2000
Inventor: Hidenori FUNAMIZU Japan
Residence: (city) Kyoto-shi, Kyoto (state/country) Japan (citizenship)
Post Office Address: c/o Central Research Institute, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya Minami Kawahara-cho,
Yamashina-ku,, Kyoto-shi, Kyoto, Japan
(Zip Code) 607-8042
- Inventor's Signature: Nobuo ISHIYAMA Date: April 5, 2000
Inventor: Nobuo ISHIYAMA Japan
Residence: (city) Kyoto-shi, Kyoto (state/country) Japan (citizenship)
Post Office Address: c/o Central Research Institute, KAKEN PHARMACEUTICAL CO., LTD., 14, Shinomiya Minami Kawahara-cho,
Yamashina-ku, Kyoto-shi, Kyoto, Japan
(Zip Code) 607-8042

FOR ADDITIONAL INVENTORS, check box ☒ and attach sheet with same information and signature and date for each.

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION

Nixon & Vanderhye P.C. (12/95)

Page 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

3. Inventor's Signature: *Satoru Ikegami* Date: April 5, 2000
 Inventor: Satoru IKEGAMI
 (first) (last)
 Residence: (city) Kyoto-shi, Kyoto MI (state/country) Japan
 (citizenship)
 Post Office Address: c/o Central Research Institute, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya Minami Kawahara-cho,
Yamashina-ku., Kyoto-shi, Kyoto, Japan
 (Zip Code) 607-8042
4. Inventor's Signature: *Tadashi Okuno* Date: April 5, 2000
 Inventor: Tadashi OKUNO
 (first) (last)
 Residence: (city) Kyoto-shi, Kyoto MI (state/country) Japan
 (citizenship)
 Post Office Address: c/o Central Research Institute, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya Minami Kawahara-cho,
Yamashina-ku., Kyoto-shi, Kyoto, Japan
 (Zip Code) 607-8042
5. Inventor's Signature: *Kiyoshi Inoguchi* Date: April 5, 2000
 Inventor: Kiyoshi INOBUCHI
 (first) (last)
 Residence: (city) Kyoto-shi, Kyoto MI (state/country) Japan
 (citizenship)
 Post Office Address: c/o Central Research Institute, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya Minami Kawahara-cho,
Yamashina-ku., Kyoto-shi, Kyoto, Japan
 (Zip Code) 607-8042
6. Inventor's Signature: *Ping Huang* Date: April 12, 2000
 Inventor: Ping HUANG
 (first) (last)
 Residence: (city) Mountain View CA (state/country) California, U.S.A.
 (citizenship)
 Post Office Address: c/o Molecular Research Institute, 2495 Old Middlefield Way, Mountain View, California, U.S.A.
 (Zip Code) 94043
7. Inventor's Signature: *Gilda Loew* Date: April 12, 2000
 Inventor: Gilda LOEW
 (first) (last)
 Residence: (city) Mountain View CA (state/country) California, U.S.A.
 (citizenship)
 Post Office Address: c/o Molecular Research Institute, 2495 Old Middlefield Way., Mountain View, California, U.S.A.
 (Zip Code) 94043